アクロレインのマウスを用いた吸入によるがん原性試験報告書

試験番号：0817

TABLES

TABLES

TABLES (CONTINUED)

TABLES (CONTINUED)

TABLE A

CONCENTRATIONS OF ACROLEIN IN THE INHALATION CHAMBER OF THE INHALATION CARCINOGENICITY STUDY

CONCENTRATIONS OF ACROLEIN IN THE INHALATION CHAMBER
OF THE INHALATION CARCINOGENICITY STUDY

Group Name	Concentration(ppm) Mean ± S.D.
Control	0.00 ± 0.00
0.1 ppm	0.10 ± 0.00
0.4 ppm	0.40 ± 0.00
1.6 ppm	1.60 ± 0.01

TABLE B1

SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
0.1ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.4ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0
1.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	47/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	94.0
0.1ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0
0.4ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
1.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0
0.1ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
0.4ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0
1.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0	92.0
0.1ppm	50	48/50	48/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	46/50	46/50	46/50
		96.0	96.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0	92.0	92.0	92.0	92.0
0.4ppm	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0
1.6ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	45/50	45/50	45/50	45/50	45/50
		92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	90.0	90.0	90.0	90.0	90.0	90.0
0.1ppm	50	46/50	46/50	45/50	45/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	43/50	43/50	43/50
		92.0	92.0	90.0	90.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	86.0	86.0	86.0
0.4ppm	50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	46/50	45/50	44/50	44/50	44/50	44/50
		92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	92.0	90.0	88.0	88.0	88.0	88.0
1.6ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50	47/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0	94.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	45/50	45/50	45/50	45/50	42/50	42/50	42/50	40/50	38/50	37/50	37/50	34/50	33/50	33/50
		90.0	90.0	90.0	90.0	84.0	84.0	84.0	80.0	76.0	74.0	74.0	68.0	66.0	66.0
0.1ppm	50	43/50	43/50	43/50	43/50	43/50	43/50	42/50	41/50	39/50	34/50	33/50	32/50	29/50	28/50
		86.0	86.0	86.0	86.0	86.0	86.0	84.0	82.0	78.0	68.0	66.0	64.0	58.0	56.0
0.4ppm	50	43/50	42/50	42/50	42/50	42/50	41/50	39/50	39/50	38/50	35/50	34/50	32/50	31/50	30/50
		86.0	84.0	84.0	84.0	84.0	82.0	78.0	78.0	76.0	70.0	68.0	64.0	62.0	60.0
1.6ppm	50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	47/50	45/50	44/50	44/50	42/50	40/50	37/50
		94.0	94.0	94.0	94.0	94.0	94.0	94.0	94.0	90.0	88.0	88.0	84.0	80.0	74.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93
SEX : MALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93
Control	50	32/50	29/50	26/50	23/50	23/50	18/50	17/50	15/50	15/50	11/50
		64.0	58.0	52.0	46.0	46.0	36.0	34.0	30.0	30.0	22.0
0.1ppm	50	24/50	22/50	22/50	22/50	22/50	19/50	19/50	18/50	17/50	15/50
		48.0	44.0	44.0	44.0	44.0	38.0	38.0	36.0	34.0	30.0
0.4ppm	50	30/50	30/50	28/50	26/50	19/50	17/50	14/50	14/50	14/50	14/50
		60.0	60.0	56.0	52.0	38.0	34.0	28.0	28.0	28.0	28.0
1.6ppm	50	35/50	33/50	31/50	30/50	28/50	25/50	24/50	23/50	16/50	15/50
		70.0	66.0	62.0	60.0	56.0	50.0	48.0	46.0	32.0	30.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE B2

SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 0	1	2	3	4	5	6	7	8	9	10	11	12	13
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.1ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0
0.4ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817 SURVIVAL ANIMAL NUMBERS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99
SEX : FEMALE

Group Name	Animals At start	Administration (Weeks) 14	15	16	17	18	19	20	21	22	23	24	25	26	27
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.1ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0
0.4ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1.6ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 28	29	30	31	32	33	34	35	36	37	38	39	40	41
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
0.1ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0
0.4ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1.6ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 42	43	44	45	46	47	48	49	50	51	52	53	54	55
Control	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	49/50	49/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	98.0	98.0
0.1ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
0.4ppm	50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50	50/50
		100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0
1.6ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817 SURVIVAL ANIMAL NUMBERS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99
SEX : FEMALE

Group Name	Animals At start	Administration (Weeks) 56	57	58	59	60	61	62	63	64	65	66	67	68	69
Control	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	47/50	45/50	45/50	45/50	45/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	94.0	90.0	90.0	90.0	90.0
0.1ppm	50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50	48/50
		96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0	96.0
0.4ppm	50	50/50	50/50	50/50	50/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	48/50	48/50	47/50
		100.0	100.0	100.0	100.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	96.0	96.0	94.0
1.6ppm	50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	49/50	48/50	48/50	47/50	47/50
		98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	98.0	96.0	96.0	94.0	94.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817 SURVIVAL ANIMAL NUMBERS

ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]

REPORT TYPE : A2 99

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks) 70	71	72	73	74	75	76	77	78	79	80	81	82	83
Control	50	45/50	45/50	45/50	45/50	45/50	45/50	44/50	44/50	42/50	42/50	41/50	41/50	39/50	38/50
		90.0	90.0	90.0	90.0	90.0	90.0	88.0	88.0	84.0	84.0	82.0	82.0	78.0	76.0
0.1ppm	50	48/50	47/50	47/50	47/50	47/50	46/50	45/50	45/50	45/50	45/50	45/50	43/50	43/50	42/50
		96.0	94.0	94.0	94.0	94.0	92.0	90.0	90.0	90.0	90.0	90.0	86.0	86.0	84.0
0.4ppm	50	47/50	47/50	45/50	43/50	43/50	43/50	41/50	41/50	40/50	40/50	39/50	39/50	37/50	37/50
		94.0	94.0	90.0	86.0	86.0	86.0	82.0	82.0	80.0	80.0	78.0	78.0	74.0	74.0
1.6ppm	50	47/50	46/50	46/50	46/50	46/50	46/50	45/50	45/50	45/50	45/50	43/50	42/50	42/50	42/50
		94.0	92.0	92.0	92.0	92.0	92.0	90.0	90.0	90.0	90.0	86.0	84.0	84.0	84.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817 SURVIVAL ANIMAL NUMBERS

ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]

REPORT TYPE : A2 99

SEX : FEMALE

Group Name	Animals At start	Administration (Weeks) 84	85	86	87	88	89	90	91	92	93	94	95	96	97
Control	50	35/50	33/50	33/50	31/50	31/50	31/50	29/50	27/50	26/50	25/50	23/50	21/50	17/50	15/50
		70.0	66.0	66.0	62.0	62.0	62.0	58.0	54.0	52.0	50.0	46.0	42.0	34.0	30.0
0.1ppm	50	42/50	39/50	38/50	37/50	36/50	33/50	31/50	31/50	31/50	29/50	26/50	25/50	22/50	21/50
		84.0	78.0	76.0	74.0	72.0	66.0	62.0	62.0	62.0	58.0	52.0	50.0	44.0	42.0
0.4ppm	50	35/50	33/50	33/50	32/50	32/50	28/50	27/50	26/50	23/50	21/50	21/50	20/50	19/50	18/50
		70.0	66.0	66.0	64.0	64.0	56.0	54.0	52.0	46.0	42.0	42.0	40.0	38.0	36.0
1.6ppm	50	39/50	39/50	38/50	37/50	37/50	37/50	36/50	36/50	35/50	33/50	31/50	28/50	26/50	25/50
		78.0	78.0	76.0	74.0	74.0	74.0	72.0	72.0	70.0	66.0	62.0	56.0	52.0	50.0

Number of survival/ Number of effective animals
Survival rate(%)

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99
SEX : FEMALE

SURVIVAL ANIMAL NUMBERS

Group Name	Animals At start	Administration (Weeks) 98	99
Control	50	13/50	11/50
		26.0	22.0
0.1ppm	50	20/50	18/50
		40.0	36.0
0.4ppm	50	15/50	14/50
		30.0	28.0
1.6ppm	50	21/50	19/50
		42.0	38.0

Number of survival/ Number of effective animals
Survival rate(%)

TABLE C1

CLINICAL OBSERVATION : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	1	1	1	1	1	1	1	1	1	2	2	2	3	3
	0.1ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	3	3	3	3	3	3	3	3	3	3	3	3	3	3
	0.1ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	2
	1.6ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	3	3	3	3	3	3	3	3	3	3	4	4	4	4
	0.1ppm	2	3	3	3	3	3	3	4	4	4	4	4	4	4
	0.4ppm	2	2	2	2	2	2	3	3	3	3	3	3	3	3
	1.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	1	1	1	1	1	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	4	4	4	4	4	4	4	5	5	5	5	5	5	5
	0.1ppm	4	5	5	5	5	5	5	5	6	6	7	7	7	7
	0.4ppm	3	3	3	3	3	3	3	3	4	5	5	5	5	6
	1.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	2	2
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	1	1	1	1	0	0	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	1	1	1	1	1	1	1	1	1	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	1	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	5	5	5	8	8	8	10	11	12	12	13	13	13	14
	0.1ppm	7	7	7	7	7	7	8	10	14	14	15	17	18	21
	0.4ppm	7	7	7	7	7	9	9	10	13	14	16	17	18	18
	1.6ppm	2	2	2	2	2	2	2	3	4	4	5	6	8	10
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	1	1	1	3	4	4	4
	0.1ppm	0	0	0	0	0	1	1	1	2	3	3	4	4	5
	0.4ppm	1	1	1	1	2	2	2	2	2	2	2	2	2	2
	1.6ppm	1	1	1	1	1	1	1	2	2	2	3	4	5	5
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	1	1	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	1	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	1	1	1	1	1	1	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	1	0	0	0	0	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7
DEATH	Control	17	20	22	22	23	24	25	25	29
	0.1ppm	22	22	22	22	25	25	26	27	29
	0.4ppm	18	20	21	25	26	28	28	28	28
	1.6ppm	11	13	14	15	17	17	18	25	26
MORIBUND SACRIFICE	Control	4	4	5	5	9	9	10	10	10
	0.1ppm	6	6	6	6	6	6	6	6	6
	0.4ppm	2	2	3	6	7	8	8	8	8
	1.6ppm	6	6	6	7	8	9	9	9	9
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	1	1	1	1	1	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	1	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	1	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1
	1.6ppm	1	1	1	1	0	1	1	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	1	0	1	0	0	0	0
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	2	2	2
	0.4ppm	0	1	1	2	2	1	1	2	1	1	2	2	2	3
	1.6ppm	0	0	0	0	3	3	3	2	2	2	2	2	2	2
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	1	1	1	1	2	2	2	2	1	1	1	1	2
	0.1ppm	2	2	2	5	5	5	5	4	4	4	4	4	4	4
	0.4ppm	4	4	4	4	4	5	5	5	5	5	5	5	5	5
	1.6ppm	2	2	2	2	2	2	2	2	2	2	3	3	3	3
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	2	2	1	1	1	2	3	2	2	2
	0.1ppm	0	0	0	1	2	2	2	1	1	2	2	2	2	2
	0.4ppm	1	1	1	2	2	1	1	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.1ppm	4	4	4	4	4	4	4	4	4	4	4	4	4	4
	0.4ppm	5	5	5	5	5	5	5	5	5	5	5	4	4	4
	1.6ppm	3	3	3	3	3	3	3	3	3	2	2	2	2	2
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	1	1	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	0.4ppm	1	1	1	1	1	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	2	2	2	2	2	2	2	1	1	1	1	1	1	1
	0.1ppm	2	2	2	2	2	2	3	3	3	3	3	3	3	3
	0.4ppm	0	0	0	0	0	0	1	2	3	3	3	3	3	3
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	2	2	2	2	2	2	2	2	2	2	1	1	1	1
	0.1ppm	4	4	4	4	4	4	4	3	3	3	3	4	4	4
	0.4ppm	4	4	4	4	4	4	3	3	3	3	3	3	3	3
	1.6ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	2	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
GUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	2	2	2	2	1	1	1	1	2	3	3	3
	0.1ppm	3	1	1	1	1	1	0	0	0	0	1	1	1	1
	0.4ppm	3	3	3	3	3	3	3	3	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	0
INTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.1ppm	4	4	4	4	4	4	4	4	4	4	4	5	5	5
	0.4ppm	3	3	3	3	3	3	3	3	3	3	3	3	3	2
	1.6ppm	2	2	3	3	3	3	3	3	3	3	3	3	3	3
M.NOSE	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	1	1	1	1	1	1	1	2	1	1	1
	0.1ppm	1	1	1	1	1	0	0	0	0	0	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
GUM	Control	0	0	1	1	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	3	3	3	3	3	3	3	3	6	6	6	6	5	5
	0.1ppm	1	1	0	0	0	0	0	0	0	1	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	4	4	3	3	4
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	1	1	2	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	5	5	5	5	5	5	5	5	5	5	4	4	3	3
	0.4ppm	2	2	2	3	3	2	2	2	2	2	2	2	2	2
	1.6ppm	3	3	3	3	3	3	3	2	3	3	3	3	3	3
M.NOSE	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	1	1	1	1	1	1	1	1	1	1	1	1	0	0
	0.1ppm	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	3	3	2	2	2
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7
GUM	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
CLOSED EYELID	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	4	3	3	3	3	2	1	1	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	4	4	5	4	4	3	3	3	3
	1.6ppm	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	3	3	3	3	3	4	3	3	3
	0.4ppm	2	2	2	2	2	2	2	2	2
	1.6ppm	3	3	3	2	2	2	2	1	1
M.NOSE	Control	1	1	1	1	1	1	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
M.EYE	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	2	2	2	1	1	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1 93

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : MALE

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.GENITALIA	Control	0	0	0	0	1	1	1	1	1	2	3	2	2	2
	0.1ppm	0	0	0	1	2	2	2	1	1	1	1	1	1	1
	0.4ppm	0	0	0	1	1	1	1	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.GENITALIA	Control	2	2	2	2	2	2	2	1	1	1	1	1	1	1
	0.1ppm	1	1	1	1	1	1	1	2	2	2	2	2	2	2
	0.4ppm	0	0	0	0	0	0	0	1	2	2	2	2	2	2
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	1	1	1	0	0	0	0
	0.1ppm	1	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.GENITALIA	Control	1	1	2	1	1	1	0	0	0	0	0	0	0	0
	0.1ppm	2	0	0	0	0	1	0	0	0	0	0	0	0	0
	0.4ppm	2	2	2	2	2	2	2	2	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	0
M.TAIL	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	1	1	1	1	1	1	1	1	1	1	1	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	1	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.GENITALIA	Control	0	0	0	0	0	0	0	0	3	3	3	3	3	3
	0.1ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.TAIL	Control	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EROSION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	1	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	1	1	1	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	1	1	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	1	2	1	1	0	0	0	0	0	2	0
	0.4ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7
M.GENITALIA	Control	2	1	1	1	1	1	1	1	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	2	2	2	2	2	2	2
	1.6ppm	0	0	0	0	0	0	0	0	0
M.TAIL	Control	1	1	1	1	1	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	1	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	1	0	0	0	0	0
EROSION	Control	1	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
CRUSTA	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	1	1	1	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
PROLAPSE OF PENIS	Control	0	1	1	1	1	1	1	1	0
	0.1ppm	0	0	0	0	0	0	0	0	1
	0.4ppm	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	1	1	0	1	0	0	0	1	0
	0.1ppm	0	0	0	0	0	0	0	0	1
	0.4ppm	0	0	1	0	0	0	0	0	0
	1.6ppm	2	1	2	1	2	1	2	0	0

TABLE C2

CLINICAL OBSERVATION : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	1	1	1	1	1	1	1	1	1
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	2	2	2	2	2
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
DEATH	Control	0	0	0	0	0	0	0	0	0	0	0	1	1	2
	0.1ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2 99

CLINICAL OBSERVATION (SUMMARY)
ALL ANIMALS

SEX : FEMALE

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
DEATH	Control	2	2	2	2	2	2	2	2	3	4	4	4	4	4
	0.1ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	2
	0.4ppm	0	0	0	1	1	1	1	1	1	1	1	1	2	2
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	1
MORIBUND SACRIFICE	Control	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	1.6ppm	1	1	1	1	1	1	1	1	1	2	2	2	2	2
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	1	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	1	0	0	0	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
DEATH	Control	4	4	4	4	4	4	4	6	6	7	7	9	10	12
	0.1ppm	3	3	3	3	3	4	4	4	4	4	5	5	6	6
	0.4ppm	2	3	4	4	4	6	6	7	7	8	8	10	10	12
	1.6ppm	2	2	2	2	2	3	3	3	3	5	6	6	6	7
MORIBUND SACRIFICE	Control	1	1	1	1	1	2	2	2	2	2	2	2	2	3
	0.1ppm	0	0	0	0	1	1	1	1	1	1	2	2	2	2
	0.4ppm	1	2	3	3	3	3	3	3	3	3	3	3	3	3
	1.6ppm	2	2	2	2	2	2	2	2	2	2	2	2	2	4
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	0	0	0	1	1	0	1	0
	0.1ppm	0	0	0	2	1	0	0	0	0	1	0	0	0	0
	0.4ppm	1	1	0	0	1	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	1	0	0	0	0	1	0	0	1	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
DEATH	Control	13	13	14	14	14	16	17	17	18	20	22	26	28	30
	0.1ppm	8	8	8	9	12	14	14	14	16	19	20	22	23	24
	0.4ppm	12	12	12	12	15	16	16	19	20	20	21	22	23	26
	1.6ppm	7	7	8	8	8	9	9	10	12	13	15	16	17	21
MORIBUND SACRIFICE	Control	4	4	5	5	5	5	6	7	7	7	7	7	7	7
	0.1ppm	3	4	5	5	5	5	5	5	5	5	5	6	6	6
	0.4ppm	5	5	6	6	7	7	8	8	9	9	9	9	9	9
	1.6ppm	4	5	5	5	5	5	5	5	5	6	7	8	8	8
HUNCHBACK POSITION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PARALYTIC GAIT	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
SOILED	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
PILOERECTION	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	1	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
FROG BELLY	Control	0	0	0	0	0	0	1	0	0	0	1	0	0	0
	0.1ppm	0	0	0	0	0	0	1	2	3	1	1	1	1	1
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	2	1	1
	1.6ppm	0	0	0	0	0	0	0	1	1	2	1	1	0	0
PROLAPSE OF ANUS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
SOILED PERI-GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7
DEATH	Control	31
	0.1ppm	25
	0.4ppm	27
	1.6ppm	23
MORIBUND SACRIFICE	Control	8
	0.1ppm	7
	0.4ppm	9
	1.6ppm	8
HUNCHBACK POSITION	Control	0
	0.1ppm	1
	0.4ppm	0
	1.6ppm	0
PARALYTIC GAIT	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
SOILED	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
PILOERECTION	Control	0
	0.1ppm	1
	0.4ppm	0
	1.6ppm	1
FROG BELLY	Control	0
	0.1ppm	2
	0.4ppm	1
	1.6ppm	0
PROLAPSE OF ANUS	Control	0
	0.1ppm	0
	0.4ppm	1
	1.6ppm	0
SOILED PERI-GENITALIA	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	1	1	0	0	0	0	0	0	0	0	0
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	0	0	0	0	1	1	2	2	2	2	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	1	1	1	1	1	1	1	1	1	1	1	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	1	1	1	1	1	1	1	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	1	1	1	1	1	1	1	2	3
	1.6ppm	0	0	0	0	0	0	0	1	1	1	2	1	1	0
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
EXTERNAL MASS	Control	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	2	2	2	2	2	2
	0.4ppm	0	0	0	0	0	0	0	0	0	1	1	2	2	1
	1.6ppm	1	1	1	1	1	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	0	0	0	2	2	2	2	1	1	1	1	0	1	1
	0.1ppm	0	0	1	1	0	0	0	0	0	1	1	1	0	1
	0.4ppm	3	3	2	3	3	1	1	0	0	1	2	1	1	1
	1.6ppm	0	0	1	2	2	1	1	1	1	3	2	2	3	2
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	1	1	1	2	1
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
EXOPHTHALMOS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
CORNEAL OPACITY	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EXTERNAL MASS	Control	0	1	1	1	1	1	0	0	0	0	0	0	0	0
	0.1ppm	2	2	2	2	2	2	2	2	2	1	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	1	2	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
INTERNAL MASS	Control	2	2	1	1	0	0	0	0	0	1	1	1	0	0
	0.1ppm	1	1	2	3	1	1	1	1	1	0	0	2	2	2
	0.4ppm	2	2	2	2	2	2	2	2	2	2	2	2	3	3
	1.6ppm	2	1	2	1	1	1	2	2	2	2	2	3	4	3
M.HEAD	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.NECK	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.FORELIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	1	1	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.BREAST	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	1	1	1	1	1	1	1	1	1	1	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.ABDOMEN	Control	0	1	1	1	1	1	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 99-7
EXOPHTHALMOS	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
CORNEAL OPACITY	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
EXTERNAL MASS	Control	0
	0.1ppm	1
	0.4ppm	0
	1.6ppm	0
INTERNAL MASS	Control	0
	0.1ppm	4
	0.4ppm	4
	1.6ppm	3
M.HEAD	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.NECK	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.FORELIMB	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.BREAST	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.ABDOMEN	Control	0
	0.1ppm	1
	0.4ppm	0
	1.6ppm	0

Clinical sign	Group Name	Administration Week-day 1-7	2-7	3-7	4-7	5-7	6-7	7-7	8-7	9-7	10-7	11-7	12-7	13-7	14-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 15-7	16-7	17-7	18-7	19-7	20-7	21-7	22-7	23-7	24-7	25-7	26-7	27-7	28-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	1	1	1	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 29-7	30-7	31-7	32-7	33-7	34-7	35-7	36-7	37-7	38-7	39-7	40-7	41-7	42-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 43-7	44-7	45-7	46-7	47-7	48-7	49-7	50-7	51-7	52-7	53-7	54-7	55-7	56-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	1	1	1	1	1	1	1
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	1	1	1	1	1	1	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	1	1	1	1	1	1	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Clinical sign	Group Name	Administration Week-day 57-7	58-7	59-7	60-7	61-7	62-7	63-7	64-7	65-7	66-7	67-7	68-7	69-7	70-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	1	1	1	1	1	1	1	1	1	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	1	1	1	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	1	1	1	1	1

Clinical sign	Group Name	Administration Week-day 71-7	72-7	73-7	74-7	75-7	76-7	77-7	78-7	79-7	80-7	81-7	82-7	83-7	84-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	1	1	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	1	1	1	1	1	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	2	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	1	1	1	1	1	1	1	1	1	1	1
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	0	0	0	0	0	1	1	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	1	0	0	0	0
	0.4ppm	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	1	0	0	1	0

Clinical sign	Group Name	Administration Week-day 85-7	86-7	87-7	88-7	89-7	90-7	91-7	92-7	93-7	94-7	95-7	96-7	97-7	98-7
M.ANTERIOR.DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.POSTERIOR DORSUM	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	1	1	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.HINDLIMB	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
M.GENITALIA	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
EDEMA	Control	0	0	0	0	1	0	0	0	0	0	0	0	0	0
	0.1ppm	0	1	0	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
TORTICOLLIS	Control	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0.1ppm	1	1	1	0	0	0	0	0	0	0	0	0	0	0
	0.4ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	1.6ppm	0	0	0	0	0	0	0	0	0	0	0	0	0	0
IRREGULAR BREATHING	Control	0	0	0	0	1	2	0	0	0	0	0	1	0	0
	0.1ppm	0	0	0	0	0	0	0	0	1	0	0	1	0	0
	0.4ppm	0	0	0	0	0	0	2	1	0	0	0	1	0	0
	1.6ppm	0	0	0	0	0	0	0	0	1	0	0	2	2	0

Clinical sign	Group Name	Administration Week-day 99-7
M.ANTERIOR.DORSUM	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.POSTERIOR DORSUM	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.HINDLIMB	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
M.GENITALIA	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
EDEMA	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
TORTICOLLIS	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	0
IRREGULAR BREATHING	Control	0
	0.1ppm	0
	0.4ppm	0
	1.6ppm	1

TABLE D1

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : C 93
SEX : MALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No.of Surviv. <50>	0.1ppm Av.Wt.	0.1ppm % of cont. <50>	0.1ppm No.of Surviv.	0.4ppm Av.Wt.	0.4ppm % of cont. <50>	0.4ppm No.of Surviv.	1.6ppm Av.Wt.	1.6ppm % of cont. <50>	1.6ppm No.of Surviv.
0	24.0 (50)	50/50	24.0 (50)	100	50/50	24.0 (50)	100	50/50	24.0 (50)	100	50/50
1	25.4 (50)	50/50	25.2 (50)	99	50/50	25.3 (50)	100	50/50	24.4 (50)	96	50/50
2	26.2 (50)	50/50	25.9 (50)	99	50/50	26.0 (50)	99	50/50	25.3 (50)	97	50/50
3	27.0 (50)	50/50	26.3 (50)	97	50/50	26.9 (50)	100	50/50	25.7 (50)	95	50/50
4	27.3 (50)	50/50	26.4 (50)	97	50/50	27.4 (50)	100	50/50	26.1 (50)	96	50/50
5	27.7 (49)	49/50	26.8 (50)	97	50/50	27.6 (50)	100	50/50	26.6 (50)	96	50/50
6	28.2 (49)	49/50	27.4 (50)	97	50/50	28.1 (50)	100	50/50	26.8 (50)	95	50/50
7	28.8 (49)	49/50	27.9 (50)	97	50/50	28.6 (50)	99	50/50	27.3 (50)	95	50/50
8	29.1 (49)	49/50	28.4 (50)	98	50/50	29.1 (50)	100	50/50	27.8 (50)	96	50/50
9	29.6 (49)	49/50	28.6 (50)	97	50/50	29.6 (49)	100	49/50	27.8 (50)	94	50/50
10	30.2 (49)	49/50	29.0 (50)	96	50/50	30.1 (49)	100	49/50	28.2 (50)	93	50/50
11	30.8 (49)	49/50	29.4 (50)	95	50/50	30.7 (49)	100	49/50	28.5 (50)	93	50/50
12	31.2 (49)	49/50	29.7 (50)	95	50/50	31.2 (49)	100	49/50	28.9 (50)	93	50/50
13	31.7 (49)	49/50	29.8 (50)	94	50/50	31.7 (49)	100	49/50	29.2 (50)	92	50/50
14	32.5 (49)	49/50	30.7 (50)	94	50/50	32.2 (49)	99	49/50	29.6 (50)	91	50/50
18	34.4 (49)	49/50	33.1 (50)	96	50/50	33.9 (49)	99	49/50	31.3 (50)	91	50/50
22	36.0 (49)	49/50	35.2 (49)	98	49/50	35.9 (49)	100	49/50	32.8 (50)	91	50/50
26	37.2 (48)	48/50	36.4 (49)	98	49/50	37.3 (49)	100	49/50	34.2 (50)	92	50/50
30	39.1 (47)	47/50	37.6 (49)	96	49/50	38.9 (49)	99	49/50	34.9 (50)	89	50/50
34	40.5 (47)	47/50	39.0 (49)	96	49/50	40.6 (49)	100	49/50	36.2 (50)	89	50/50
38	41.4 (47)	47/50	40.2 (49)	97	49/50	41.1 (49)	99	49/50	36.9 (49)	89	49/50
42	42.2 (47)	47/50	40.9 (48)	97	48/50	41.7 (47)	99	47/50	37.5 (49)	89	49/50
46	42.9 (47)	47/50	42.1 (47)	98	47/50	42.6 (47)	99	47/50	38.1 (49)	89	49/50
50	43.1 (47)	47/50	41.9 (46)	97	46/50	43.0 (46)	100	46/50	38.3 (49)	89	49/50
54	42.8 (46)	46/50	41.3 (46)	96	46/50	42.8 (46)	100	46/50	38.1 (49)	89	49/50
58	41.9 (46)	46/50	41.1 (45)	98	45/50	41.8 (46)	100	46/50	37.4 (49)	89	49/50
62	40.2 (46)	46/50	39.9 (45)	99	45/50	40.4 (46)	100	46/50	36.7 (49)	91	49/50
66	38.6 (45)	45/50	38.9 (44)	101	44/50	39.5 (44)	102	44/50	35.2 (48)	91	48/50
70	37.7 (45)	45/50	38.0 (43)	101	43/50	38.0 (43)	101	43/50	34.8 (47)	92	47/50
74	36.4 (42)	42/50	35.5 (43)	98	43/50	37.1 (42)	102	42/50	34.0 (47)	93	47/50
78	35.1 (38)	38/50	34.2 (39)	97	39/50	35.5 (38)	101	38/50	32.0 (45)	91	45/50
82	34.7 (33)	33/50	34.8 (29)	100	29/50	35.6 (31)	103	31/50	31.6 (40)	91	40/50
86	34.4 (26)	26/50	34.5 (22)	100	22/50	33.8 (28)	98	28/50	32.5 (31)	94	31/50
90	35.8 (17)	17/50	34.4 (19)	96	19/50	36.8 (14)	103	14/50	31.7 (24)	89	24/50
93	37.6 (11)	11/50	33.4 (15)	89	15/50	35.6 (14)	95	14/50	31.3 (15)	83	15/50

< >:No.of effective animals, ( ):No.of measured animals Av.Wt. : g

TABLE D2

BODY WEIGHT CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : C 99
SEX : FEMALE

MEAN BODY WEIGHTS AND SURVIVAL

Week on Study	Control Av.Wt.	Control No. of Surviv. <50>	0.1ppm Av.Wt.	0.1ppm % of cont. <50>	0.1ppm No. of Surviv.	0.4ppm Av.Wt.	0.4ppm % of cont. <50>	0.4ppm No. of Surviv.	1.6ppm Av.Wt.	1.6ppm % of cont. <50>	1.6ppm No. of Surviv.
0	19.8 (50)	50/50	19.8 (50)	100	50/50	19.8 (50)	100	50/50	19.8 (50)	100	50/50
1	20.3 (50)	50/50	20.1 (50)	99	50/50	20.3 (50)	100	50/50	19.6 (50)	97	50/50
2	21.1 (50)	50/50	20.6 (50)	98	50/50	20.8 (50)	99	50/50	20.5 (50)	97	50/50
3	21.5 (50)	50/50	21.2 (50)	99	50/50	21.5 (50)	100	50/50	21.1 (50)	98	50/50
4	22.1 (50)	50/50	21.5 (50)	97	50/50	22.1 (50)	100	50/50	21.6 (50)	98	50/50
5	22.6 (50)	50/50	22.0 (50)	97	50/50	22.4 (50)	99	50/50	22.2 (50)	98	50/50
6	23.3 (50)	50/50	22.7 (50)	97	50/50	23.0 (50)	99	50/50	22.6 (50)	97	50/50
7	23.8 (50)	50/50	22.9 (50)	96	50/50	23.7 (50)	100	50/50	23.1 (50)	97	50/50
8	24.3 (50)	50/50	23.3 (50)	96	50/50	24.3 (50)	100	50/50	23.6 (50)	97	50/50
9	24.5 (50)	50/50	23.8 (50)	97	50/50	24.2 (50)	99	50/50	23.6 (50)	96	50/50
10	24.7 (50)	50/50	24.1 (50)	98	50/50	24.5 (50)	99	50/50	23.8 (50)	96	50/50
11	24.7 (50)	50/50	24.3 (50)	98	50/50	24.9 (50)	101	50/50	24.1 (50)	98	50/50
12	25.1 (50)	50/50	24.4 (50)	97	50/50	24.9 (50)	99	50/50	24.4 (50)	97	50/50
13	25.3 (50)	50/50	24.3 (49)	96	49/50	25.1 (50)	99	50/50	24.8 (50)	98	50/50
14	25.8 (50)	50/50	24.9 (49)	97	49/50	25.3 (50)	98	50/50	25.1 (50)	97	50/50
18	26.7 (50)	50/50	26.3 (49)	99	49/50	26.2 (50)	98	50/50	25.6 (50)	96	50/50
22	27.3 (50)	50/50	26.7 (49)	98	49/50	27.1 (50)	99	50/50	26.2 (49)	96	49/50
26	27.7 (50)	50/50	27.2 (49)	98	49/50	27.7 (50)	100	50/50	27.0 (49)	97	49/50
30	28.4 (50)	50/50	27.7 (49)	98	49/50	28.4 (50)	100	50/50	27.2 (49)	96	49/50
34	28.6 (50)	50/50	28.5 (49)	100	49/50	28.7 (50)	100	50/50	27.9 (49)	98	49/50
38	29.3 (50)	50/50	28.5 (48)	97	48/50	28.9 (50)	99	50/50	27.7 (49)	95	49/50
42	29.3 (50)	50/50	28.9 (48)	99	48/50	29.6 (50)	101	50/50	27.9 (49)	95	49/50
46	30.1 (50)	50/50	29.5 (48)	98	48/50	29.5 (50)	98	50/50	28.4 (49)	94	49/50
50	30.2 (50)	50/50	29.0 (48)	96	48/50	29.9 (50)	99	50/50	28.3 (49)	94	49/50
54	30.1 (49)	49/50	29.2 (48)	97	48/50	29.8 (50)	99	50/50	28.3 (49)	94	49/50
58	29.7 (48)	48/50	29.8 (48)	100	48/50	29.8 (50)	100	50/50	28.1 (49)	95	49/50
62	30.4 (48)	48/50	29.1 (48)	96	48/50	29.9 (49)	98	49/50	28.0 (49)	92	49/50
66	29.8 (45)	45/50	29.3 (48)	98	48/50	29.5 (48)	99	48/50	28.0 (48)	94	48/50
70	30.3 (45)	45/50	29.6 (48)	98	48/50	29.9 (47)	99	47/50	28.4 (47)	94	47/50
74	30.2 (45)	45/50	30.2 (47)	100	47/50	30.7 (43)	102	43/50	28.9 (46)	96	46/50
78	29.8 (42)	42/50	29.3 (45)	98	45/50	29.6 (40)	99	40/50	28.3 (45)	95	45/50
82	30.1 (39)	39/50	29.6 (43)	98	43/50	30.0 (37)	100	37/50	28.6 (42)	95	42/50
86	30.4 (33)	33/50	29.9 (38)	98	38/50	30.0 (33)	99	33/50	29.1 (38)	96	38/50
90	30.1 (29)	29/50	30.2 (31)	100	31/50	30.4 (27)	101	27/50	29.6 (36)	98	36/50
94	29.5 (23)	23/50	30.1 (26)	102	26/50	30.7 (21)	104	21/50	29.3 (31)	99	31/50
98	29.7 (13)	13/50	29.6 (20)	100	20/50	32.3 (15)	109	15/50	29.5 (21)	99	21/50
99	29.0 (11)	11/50	30.2 (18)	104	18/50	32.3 (14)	111	14/50	29.2 (19)	101	19/50

< >:No.of effective animals, ( ):No.of measured animals Av.Wt. : g

TABLE D3

BODY WEIGHT CHANGES : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	24.0± 0.8	25.4± 0.9	26.2± 1.0	27.0± 1.1	27.3± 1.3	27.7± 1.3	28.2± 1.5
0.1ppm	24.0± 0.8	25.2± 0.9	25.9± 1.0	26.3± 1.1**	26.4± 1.2**	26.8± 1.2**	27.4± 1.4*
0.4ppm	24.0± 0.8	25.3± 1.1	26.0± 1.1	26.9± 1.2	27.4± 1.3	27.6± 1.7	28.1± 1.7
1.6ppm	24.0± 0.8	24.4± 0.9**	25.3± 1.0**	25.7± 1.1**	26.1± 1.1**	26.6± 1.2**	26.8± 1.2**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	28.8± 1.5	29.1± 1.7	29.6± 1.8	30.2± 1.9	30.8± 2.1	31.2± 2.2	31.7± 2.3
0.1ppm	27.9± 1.5*	28.4± 1.7	28.6± 1.7**	29.0± 1.9**	29.4± 2.2*	29.7± 2.0**	29.8± 2.3**
0.4ppm	28.6± 2.1	29.1± 2.2	29.6± 1.7	30.1± 1.9	30.7± 2.0	31.2± 2.0	31.7± 2.2
1.6ppm	27.3± 1.2**	27.8± 1.3**	27.8± 1.4**	28.2± 1.4**	28.5± 1.5**	28.9± 1.5**	29.2± 1.6**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	32.5± 2.4	34.4± 2.5	36.0± 2.8	37.2± 3.2	39.1± 3.1	40.5± 3.3	41.4± 3.5
0.1ppm	30.7± 2.4**	33.1± 2.8*	35.2± 2.7	36.4± 3.0	37.6± 3.4	39.0± 3.6	40.2± 4.0
0.4ppm	32.2± 2.2	33.9± 2.6	35.9± 3.1	37.3± 3.5	38.9± 3.9	40.6± 4.2	41.1± 4.7
1.6ppm	29.6± 1.7**	31.3± 2.0**	32.8± 2.3**	34.2± 2.6**	34.9± 2.8**	36.2± 3.1**	36.9± 3.3**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	42.2± 3.4	42.9± 3.7	43.1± 4.4	42.8± 5.1	41.9± 5.5	40.2± 5.6	38.6± 5.5
0.1ppm	40.9± 4.3	42.1± 4.4	41.9± 4.3	41.3± 5.2	41.1± 5.6	39.9± 6.1	38.9± 6.0
0.4ppm	41.7± 5.0	42.6± 5.3	43.0± 5.2	42.8± 5.5	41.8± 5.6	40.4± 6.3	39.5± 6.6
1.6ppm	37.5± 3.5**	38.1± 3.6**	38.3± 3.8**	38.1± 4.0**	37.4± 4.3**	36.7± 4.0**	35.2± 3.8*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	93
Control	37.7± 5.0	36.4± 5.8	35.1± 6.5	34.7± 6.9	34.4± 6.8	35.8± 7.2	37.6± 7.6
0.1ppm	38.0± 5.5	35.5± 5.7	34.2± 5.9	34.8± 4.7	34.5± 4.3	34.4± 4.0	33.4± 3.6
0.4ppm	38.0± 5.9	37.1± 6.0	35.5± 6.5	35.6± 6.7	33.8± 6.6	36.8± 6.0	35.6± 5.6
1.6ppm	34.8± 3.5*	34.0± 4.1	32.0± 4.0*	31.6± 4.5	32.5± 4.5	31.7± 4.2	31.3± 4.5*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE D4

BODY WEIGHT CHANGES : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 0	1	2	3	4	5	6
Control	19.8± 0.8	20.3± 0.8	21.1± 0.9	21.5± 0.9	22.1± 0.9	22.6± 1.1	23.3± 1.2
0.1ppm	19.8± 0.8	20.1± 0.8	20.6± 0.9*	21.2± 1.0	21.5± 1.0**	22.0± 1.1	22.7± 1.1*
0.4ppm	19.8± 0.8	20.3± 0.8	20.8± 0.8	21.5± 0.7	22.1± 0.8	22.4± 0.9	23.0± 0.9
1.6ppm	19.8± 0.8	19.6± 0.9**	20.5± 1.0**	21.1± 1.0	21.6± 1.0*	22.2± 1.3	22.6± 1.1**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 7	8	9	10	11	12	13
Control	23.8± 1.2	24.3± 1.3	24.5± 1.3	24.7± 1.4	24.7± 1.2	25.1± 1.4	25.3± 1.2
0.1ppm	22.9± 1.1**	23.3± 1.1**	23.8± 1.2**	24.1± 1.3*	24.3± 1.5	24.4± 1.2*	24.3± 1.3**
0.4ppm	23.7± 0.9	24.3± 1.0	24.2± 1.1	24.5± 1.1	24.9± 0.9	24.9± 0.9	25.1± 1.1
1.6ppm	23.1± 1.3**	23.6± 1.3*	23.6± 1.1**	23.8± 1.1**	24.1± 1.2**	24.4± 1.4*	24.8± 1.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 14	18	22	26	30	34	38
Control	25.8± 1.4	26.7± 1.6	27.3± 1.7	27.7± 1.8	28.4± 1.8	28.6± 1.6	29.3± 1.8
0.1ppm	24.9± 1.4**	26.3± 1.4	26.7± 1.4	27.2± 1.6	27.7± 1.9	28.5± 2.0	28.5± 1.9
0.4ppm	25.3± 1.0	26.2± 1.3	27.1± 1.5	27.7± 1.6	28.4± 1.4	28.7± 1.4	28.9± 1.6
1.6ppm	25.1± 1.1**	25.6± 1.2**	26.2± 1.2**	27.0± 1.6	27.2± 1.7**	27.9± 2.0	27.7± 1.7**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 42	46	50	54	58	62	66
Control	29.3± 1.6	30.1± 1.9	30.2± 2.4	30.1± 2.7	29.7± 2.0	30.4± 2.8	29.8± 2.0
0.1ppm	28.9± 2.0	29.5± 2.1	29.0± 2.3*	29.2± 2.1	29.8± 2.1	29.1± 2.1*	29.3± 2.0
0.4ppm	29.6± 1.6	29.5± 1.6	29.9± 1.8	29.8± 1.8	29.8± 1.7	29.9± 1.8	29.5± 2.1
1.6ppm	27.9± 1.7**	28.4± 1.8**	28.3± 1.7**	28.3± 1.5**	28.1± 1.3**	28.0± 1.5**	28.0± 1.9**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 70	74	78	82	86	90	94
Control	30.3± 1.9	30.2± 2.3	29.8± 2.5	30.1± 2.3	30.4± 2.2	30.1± 2.5	29.5± 3.0
0.1ppm	29.6± 2.3	30.2± 3.1	29.3± 1.8	29.6± 2.7	29.9± 2.4	30.2± 2.3	30.1± 3.0
0.4ppm	29.9± 2.5	30.7± 2.6	29.6± 2.3	30.0± 2.6	30.0± 3.2	30.4± 3.1	30.7± 2.8
1.6ppm	28.4± 1.7**	28.9± 1.8**	28.3± 2.1**	28.6± 2.2*	29.1± 1.9	29.6± 2.2	29.3± 3.4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

BODY WEIGHT CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week 98	99
Control	29.7± 2.8	29.0± 3.0
0.1ppm	29.6± 3.6	30.2± 4.5
0.4ppm	32.3± 3.2	32.3± 3.1*
1.6ppm	29.5± 1.9	29.2± 1.9

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E1

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : C 93
SEX : MALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week on Study	Control Av.FC.	Control No. of Surviv. <50>	0.1ppm Av.FC.	0.1ppm % of cont. <50>	0.1ppm No. of Surviv.	0.4ppm Av.FC.	0.4ppm % of cont. <50>	0.4ppm No. of Surviv.	1.6ppm Av.FC.	1.6ppm % of cont. <50>	1.6ppm No. of Surviv.
1	4.2 (50)	50/50	4.2 (50)	100	50/50	4.2 (50)	100	50/50	3.8 (50)	90	50/50
2	4.2 (50)	50/50	4.1 (50)	98	50/50	4.2 (50)	100	50/50	4.1 (50)	98	50/50
3	4.2 (50)	50/50	4.1 (50)	98	50/50	4.3 (50)	102	50/50	4.1 (50)	98	50/50
4	4.3 (50)	50/50	4.2 (50)	98	50/50	4.3 (50)	100	50/50	4.2 (50)	98	50/50
5	4.3 (49)	49/50	4.3 (50)	100	50/50	4.3 (50)	100	50/50	4.3 (50)	100	50/50
6	4.4 (49)	49/50	4.3 (50)	98	50/50	4.4 (50)	100	50/50	4.3 (50)	98	50/50
7	4.5 (49)	49/50	4.4 (50)	98	50/50	4.5 (50)	100	50/50	4.4 (50)	98	50/50
8	4.4 (49)	49/50	4.4 (50)	100	50/50	4.5 (50)	102	50/50	4.4 (50)	100	50/50
9	4.5 (49)	49/50	4.3 (50)	96	50/50	4.6 (49)	102	49/50	4.5 (50)	100	50/50
10	4.5 (49)	49/50	4.4 (50)	98	50/50	4.6 (49)	102	49/50	4.5 (50)	100	50/50
11	4.6 (49)	49/50	4.5 (50)	98	50/50	4.6 (49)	100	49/50	4.5 (50)	98	50/50
12	4.6 (49)	49/50	4.5 (50)	98	50/50	4.7 (49)	102	49/50	4.6 (50)	100	50/50
13	4.6 (49)	49/50	4.5 (50)	98	50/50	4.7 (49)	102	49/50	4.5 (50)	98	50/50
14	4.3 (49)	49/50	4.2 (50)	98	50/50	4.7 (49)	109	49/50	4.6 (50)	107	50/50
18	4.8 (49)	49/50	4.7 (50)	98	50/50	4.8 (49)	100	49/50	4.6 (50)	96	50/50
22	5.0 (49)	49/50	4.9 (49)	98	49/50	5.0 (49)	100	49/50	4.9 (50)	98	50/50
26	5.1 (48)	48/50	4.9 (49)	96	49/50	5.0 (49)	98	49/50	4.9 (50)	96	50/50
30	5.1 (47)	47/50	4.9 (49)	96	49/50	5.0 (49)	98	49/50	4.9 (50)	96	50/50
34	4.9 (47)	47/50	4.8 (49)	98	49/50	4.8 (49)	98	49/50	4.7 (50)	96	50/50
38	4.9 (47)	47/50	4.8 (49)	98	49/50	4.9 (49)	100	49/50	4.7 (49)	96	49/50
42	5.0 (47)	47/50	4.9 (48)	98	48/50	5.0 (47)	100	47/50	4.7 (49)	94	49/50
46	5.0 (47)	47/50	4.9 (47)	98	47/50	5.0 (47)	100	47/50	4.8 (49)	96	49/50
50	4.9 (47)	47/50	4.8 (46)	98	46/50	4.9 (46)	100	46/50	4.7 (49)	96	49/50
54	4.9 (46)	46/50	4.9 (46)	100	46/50	5.0 (46)	102	46/50	4.6 (49)	94	49/50
58	5.0 (46)	46/50	4.7 (45)	94	45/50	4.9 (46)	98	46/50	4.6 (49)	92	49/50
62	4.7 (46)	46/50	4.8 (45)	102	45/50	4.7 (46)	100	46/50	4.5 (49)	96	49/50
66	4.6 (45)	45/50	4.6 (44)	100	44/50	4.8 (44)	104	44/50	4.4 (48)	96	48/50
70	5.0 (45)	45/50	4.7 (43)	94	43/50	4.9 (43)	98	43/50	4.6 (47)	92	47/50
74	5.1 (42)	42/50	5.0 (43)	98	43/50	5.0 (42)	98	42/50	4.5 (47)	88	47/50
78	5.1 (38)	38/50	5.3 (39)	104	39/50	4.8 (38)	94	38/50	4.3 (45)	84	45/50
82	4.8 (33)	33/50	4.7 (29)	98	29/50	4.8 (31)	100	31/50	4.4 (40)	92	40/50
86	4.2 (26)	26/50	4.2 (22)	100	22/50	4.1 (28)	98	28/50	4.1 (31)	98	31/50
90	4.7 (17)	17/50	4.4 (19)	94	19/50	4.7 (14)	100	14/50	4.2 (24)	89	24/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC. : g

TABLE E2

FOOD CONSUMPTION CHANGES AND SURVIVAL ANIMAL NUMBERS : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : C 99
SEX : FEMALE

MEAN FOOD CONSUMPTION(FC) AND SURVIVAL

Week on Study	Control Av.FC.	Control No. of Surviv. <50>	0.1ppm Av.FC.	0.1ppm % of cont. <50>	0.1ppm No. of Surviv.	0.4ppm Av.FC.	0.4ppm % of cont. <50>	0.4ppm No. of Surviv.	1.6ppm Av.FC.	1.6ppm % of cont. <50>	1.6ppm No. of Surviv.
1	3.6 (50)	50/50	3.5 (50)	97	50/50	3.5 (50)	97	50/50	3.3 (50)	92	50/50
2	3.6 (50)	50/50	3.5 (50)	97	50/50	3.6 (50)	100	50/50	3.6 (50)	100	50/50
3	3.8 (50)	50/50	3.7 (50)	97	50/50	3.8 (50)	100	50/50	3.7 (50)	97	50/50
4	4.0 (50)	50/50	3.9 (50)	98	50/50	4.1 (50)	103	50/50	3.9 (50)	98	50/50
5	4.2 (50)	50/50	4.1 (50)	98	50/50	4.2 (50)	100	50/50	4.1 (50)	98	50/50
6	4.4 (50)	50/50	4.3 (50)	98	50/50	4.3 (50)	98	50/50	4.2 (50)	95	50/50
7	4.5 (50)	50/50	4.3 (50)	96	50/50	4.5 (50)	100	50/50	4.3 (50)	96	50/50
8	4.5 (50)	50/50	4.4 (50)	98	50/50	4.5 (50)	100	50/50	4.4 (50)	98	50/50
9	4.6 (50)	50/50	4.4 (50)	96	50/50	4.6 (50)	100	50/50	4.4 (50)	96	50/50
10	4.6 (50)	50/50	4.5 (50)	98	50/50	4.5 (50)	98	50/50	4.4 (50)	96	50/50
11	4.5 (50)	50/50	4.4 (49)	98	50/50	4.5 (50)	100	50/50	4.5 (50)	100	50/50
12	4.7 (50)	50/50	4.5 (50)	96	50/50	4.6 (50)	98	50/50	4.6 (50)	98	50/50
13	4.7 (50)	50/50	4.5 (49)	96	49/50	4.6 (50)	98	50/50	4.5 (50)	96	50/50
14	4.3 (50)	50/50	4.1 (49)	95	49/50	4.7 (50)	109	50/50	4.6 (50)	107	50/50
18	4.9 (50)	50/50	4.7 (49)	96	49/50	4.7 (50)	96	50/50	4.5 (50)	92	50/50
22	4.9 (50)	50/50	4.7 (49)	96	49/50	5.0 (50)	102	50/50	4.7 (49)	96	49/50
26	5.1 (50)	50/50	4.9 (49)	96	49/50	4.9 (50)	96	50/50	4.7 (49)	92	49/50
30	5.0 (50)	50/50	4.8 (49)	96	49/50	5.0 (50)	100	50/50	4.7 (49)	94	49/50
34	4.8 (50)	50/50	4.7 (49)	98	49/50	4.8 (50)	100	50/50	4.5 (49)	94	49/50
38	4.7 (50)	50/50	4.6 (48)	98	48/50	4.6 (50)	98	50/50	4.4 (49)	94	49/50
42	4.7 (50)	50/50	4.7 (48)	100	48/50	4.8 (50)	102	50/50	4.5 (49)	96	49/50
46	4.7 (50)	50/50	4.6 (48)	98	48/50	4.7 (50)	100	50/50	4.4 (49)	94	49/50
50	4.7 (50)	50/50	4.5 (48)	96	48/50	4.7 (50)	100	50/50	4.3 (49)	91	49/50
54	4.8 (49)	49/50	4.6 (48)	96	48/50	4.8 (50)	100	50/50	4.4 (49)	92	49/50
58	4.8 (48)	48/50	4.6 (48)	96	48/50	4.7 (50)	98	50/50	4.4 (49)	92	49/50
62	4.7 (48)	48/50	4.5 (48)	96	48/50	4.4 (49)	94	49/50	4.1 (49)	87	49/50
66	4.6 (45)	45/50	4.4 (48)	96	48/50	4.4 (48)	96	48/50	4.3 (48)	93	48/50
70	5.1 (45)	45/50	4.8 (48)	94	48/50	4.7 (47)	92	47/50	4.4 (47)	86	47/50
74	5.2 (45)	45/50	4.9 (47)	94	47/50	4.8 (43)	92	43/50	4.5 (46)	87	46/50
78	5.5 (42)	42/50	5.0 (45)	91	45/50	4.7 (40)	85	40/50	4.5 (45)	82	45/50
82	4.8 (39)	39/50	4.8 (43)	100	43/50	4.6 (37)	96	37/50	4.4 (42)	92	42/50
86	4.5 (33)	33/50	4.3 (38)	96	38/50	4.4 (33)	98	33/50	4.1 (38)	91	38/50
90	4.7 (29)	29/50	4.5 (31)	96	31/50	4.6 (27)	98	27/50	4.3 (36)	91	36/50
94	4.5 (23)	23/50	4.5 (26)	100	26/50	4.8 (21)	107	21/50	4.2 (31)	93	31/50
98	4.6 (13)	13/50	4.6 (20)	100	20/50	4.8 (15)	104	15/50	4.3 (21)	93	21/50

< >:No.of effective animals, ( ):No.of measured animals Av.FC.: g

TABLE E3

FOOD CONSUMPTION CHANGES : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	4.2± 0.2	4.2± 0.2	4.2± 0.3	4.3± 0.3	4.3± 0.2	4.4± 0.2	4.5± 0.3
0.1ppm	4.2± 0.2	4.1± 0.3	4.1± 0.3*	4.2± 0.3	4.3± 0.3	4.3± 0.3	4.4± 0.3
0.4ppm	4.2± 0.3	4.2± 0.3	4.3± 0.2	4.3± 0.3	4.3± 0.3	4.4± 0.2	4.5± 0.3
1.6ppm	3.8± 0.2**	4.1± 0.3*	4.1± 0.3	4.2± 0.3	4.3± 0.3	4.3± 0.3	4.4± 0.3

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	4.4± 0.3	4.5± 0.3	4.5± 0.3	4.6± 0.3	4.6± 0.3	4.6± 0.3	4.3± 0.4
0.1ppm	4.4± 0.3	4.3± 0.3**	4.4± 0.4	4.5± 0.4	4.5± 0.4*	4.5± 0.3	4.2± 0.4
0.4ppm	4.5± 0.3	4.6± 0.3	4.6± 0.3	4.6± 0.3	4.7± 0.3	4.7± 0.3	4.7± 0.3**
1.6ppm	4.4± 0.3	4.5± 0.3	4.5± 0.3	4.5± 0.3	4.6± 0.3	4.5± 0.3*	4.6± 0.3**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	4.8± 0.3	5.0± 0.3	5.1± 0.4	5.1± 0.3	4.9± 0.3	4.9± 0.3	5.0± 0.3
0.1ppm	4.7± 0.4	4.9± 0.3	4.9± 0.3*	4.9± 0.3**	4.8± 0.3	4.8± 0.3	4.9± 0.4
0.4ppm	4.8± 0.3	5.0± 0.3	5.0± 0.3	5.0± 0.3*	4.8± 0.3	4.9± 0.4	5.0± 0.4
1.6ppm	4.6± 0.3	4.9± 0.3	4.9± 0.3*	4.9± 0.3**	4.7± 0.3**	4.7± 0.3*	4.7± 0.3**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	5.0± 0.3	4.9± 0.4	4.9± 0.4	5.0± 0.6	4.7± 0.7	4.6± 0.7	5.0± 0.8
0.1ppm	4.9± 0.3	4.8± 0.3	4.9± 0.4	4.7± 0.5	4.8± 0.8	4.6± 0.6	4.7± 0.7
0.4ppm	5.0± 0.4	4.9± 0.3	5.0± 0.5	4.9± 0.6	4.7± 0.7	4.8± 0.7	4.9± 0.7
1.6ppm	4.8± 0.3**	4.7± 0.3**	4.6± 0.4*	4.6± 0.4**	4.5± 0.6	4.4± 0.4*	4.6± 0.6**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A1 93
SEX : MALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)
Control	5.1± 0.8	5.1± 0.9	4.8± 0.7	4.2± 0.8	4.7± 0.7
0.1ppm	5.0± 1.1	5.3± 1.0	4.7± 0.7	4.2± 0.5	4.4± 0.6
0.4ppm	5.0± 0.9	4.8± 0.6	4.8± 0.9	4.1± 0.7	4.7± 0.6
1.6ppm	4.5± 0.6**	4.3± 0.5**	4.4± 0.5*	4.1± 0.4	4.2± 0.5*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE E4

FOOD CONSUMPTION CHANGES : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 1-7(7)	2-7(7)	3-7(7)	4-7(7)	5-7(7)	6-7(7)	7-7(7)
Control	3.6± 0.3	3.6± 0.2	3.8± 0.2	4.0± 0.3	4.2± 0.3	4.4± 0.3	4.5± 0.5
0.1ppm	3.5± 0.3	3.5± 0.3	3.7± 0.3	3.9± 0.3	4.1± 0.3	4.3± 0.3	4.3± 0.3*
0.4ppm	3.5± 0.3	3.6± 0.2	3.8± 0.2	4.1± 0.2	4.2± 0.3	4.3± 0.3	4.5± 0.3
1.6ppm	3.3± 0.2**	3.6± 0.2	3.7± 0.2	3.9± 0.3*	4.1± 0.3	4.2± 0.3**	4.3± 0.4*

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 8-7(7)	9-7(7)	10-7(7)	11-7(7)	12-7(7)	13-7(7)	14-7(7)
Control	4.5± 0.5	4.6± 0.4	4.6± 0.4	4.5± 0.4	4.7± 0.3	4.7± 0.4	4.3± 0.3
0.1ppm	4.4± 0.3	4.4± 0.3	4.5± 0.4	4.4± 0.5	4.5± 0.3*	4.5± 0.7**	4.1± 0.4*
0.4ppm	4.5± 0.3	4.6± 0.3	4.5± 0.3	4.5± 0.3	4.6± 0.5	4.6± 0.3	4.7± 0.4**
1.6ppm	4.4± 0.4*	4.4± 0.4	4.4± 0.4	4.5± 0.3	4.6± 0.5	4.5± 0.4**	4.6± 0.3**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 18-7(7)	22-7(7)	26-7(7)	30-7(7)	34-7(7)	38-7(7)	42-7(7)
Control	4.9± 0.4	4.9± 0.4	5.1± 0.4	5.0± 0.4	4.8± 0.3	4.7± 0.4	4.7± 0.3
0.1ppm	4.7± 0.4*	4.7± 0.4*	4.9± 0.4	4.8± 0.4*	4.7± 0.4	4.6± 0.4	4.7± 0.4
0.4ppm	4.7± 0.4	5.0± 0.4	4.9± 0.4	5.0± 0.4	4.8± 0.4	4.6± 0.4	4.8± 0.4
1.6ppm	4.5± 0.4**	4.7± 0.4**	4.7± 0.4**	4.7± 0.4**	4.5± 0.4**	4.4± 0.4**	4.5± 0.4**

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 46-7(7)	50-7(7)	54-7(7)	58-7(7)	62-7(7)	66-7(7)	70-7(7)
Control	4.7± 0.4	4.7± 0.4	4.8± 0.4	4.8± 0.7	4.7± 0.8	4.6± 0.5	5.1± 1.1
0.1ppm	4.6± 0.4	4.5± 0.5*	4.6± 0.4	4.6± 0.4	4.5± 0.5	4.4± 0.3	4.8± 0.6
0.4ppm	4.7± 0.4	4.7± 0.5	4.8± 0.7	4.7± 0.7	4.4± 0.5*	4.4± 0.5	4.7± 0.8*
1.6ppm	4.4± 0.4**	4.3± 0.3**	4.4± 0.4**	4.4± 0.4**	4.1± 0.4**	4.3± 0.4**	4.4± 0.5**

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
UNIT : g
REPORT TYPE : A2 99
SEX : FEMALE

FOOD CONSUMPTION CHANGES (SUMMARY)
ALL ANIMALS

Group Name	Administration week-day(effective) 74-7(7)	78-7(7)	82-7(7)	86-7(7)	90-7(7)	94-7(7)	98-7(7)
Control	5.2± 1.4	5.5± 1.5	4.8± 0.6	4.5± 0.5	4.7± 0.6	4.5± 0.7	4.6± 0.6
0.1ppm	4.9± 0.6	5.0± 0.6	4.8± 0.6	4.3± 0.5	4.5± 0.5	4.5± 0.5	4.6± 0.7
0.4ppm	4.8± 0.6	4.7± 0.5**	4.6± 0.5	4.4± 0.5	4.6± 0.6	4.8± 0.8	4.8± 0.7
1.6ppm	4.5± 0.6**	4.5± 0.5**	4.4± 0.4**	4.1± 0.4**	4.3± 0.4**	4.2± 0.5	4.3± 0.4

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F1

HEMATOLOGY : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (94W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	11	6.82± 2.72	9.9± 3.9	32.6± 11.8	48.7± 2.7	14.5± 0.4	29.9± 1.7	1917± 404
0.1ppm	14	6.79± 1.96	9.6± 2.6	31.9± 8.0	48.0± 4.7	14.3± 0.9	30.0± 1.5	1753± 663
0.4ppm	14	7.73± 1.49	11.2± 2.1	36.4± 5.9	47.6± 3.3	14.5± 0.8	30.5± 1.0	1948± 355
1.6ppm	15	6.27± 2.45	9.1± 3.7	30.7± 10.9	49.9± 3.9	14.5± 0.6	29.2± 2.1	1930± 320

Significant difference : * : $P \leqq 0.05$ ** : $P \leqq 0.01$ Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (94W)

Group Name	NO. of Animals	RETICULOCYTE %	
Control	11	5.9±	4.3
0.1ppm	14	7.0±	6.8
0.4ppm	14	4.2±	3.9
1.6ppm	15	7.6±	6.2

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

HEMATOLOGY (SUMMARY)
ALL ANIMALS (94W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$		Differential WBC (%) NEUTRO		LYMPHO		MONO		EOSINO		BASO		OTHER	
Control	11	3.11±	1.83	41±	14	55±	13	2±	1	1±	1	0±	0	1±	1
0.1ppm	14	2.64±	1.95	48±	15	48±	15	2±	1	2±	1	0±	0	1±	1
0.4ppm	14	3.82±	2.18	48±	10	47±	11	3±	3	2±	1	0±	0	1±	1
1.6ppm	15	2.38±	1.57	43±	10	52±	10	2±	1	2±	1	0±	0	0±	1

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE F2

HEMATOLOGY : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

HEMATOLOGY (SUMMARY)
ALL ANIMALS (100W)

Group Name	NO. of Animals	RED BLOOD CELL $10^6/\mu\ell$	HEMOGLOBIN g/dℓ	HEMATOCRIT %	MCV fℓ	MCH pg	MCHC g/dℓ	PLATELET $10^3/\mu\ell$
Control	11	7.76± 1.56	11.2± 2.3	36.1± 6.9	46.7± 2.8	14.5± 0.6	31.1± 0.8	1304± 358
0.1ppm	17	6.91± 2.41	10.3± 3.5	33.2± 10.3	49.3± 5.8	14.9± 1.3	30.5± 2.0	1014± 433
0.4ppm	14	7.33± 1.92	10.8± 2.6	35.2± 7.6	49.1± 5.7	15.0± 1.2	30.6± 1.4	1099± 470
1.6ppm	18	6.99± 2.17	10.3± 3.1	33.1± 9.0	49.4± 8.5	15.0± 1.1	30.7± 2.2	1183± 501

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

HEMATOLOGY (SUMMARY)
ALL ANIMALS (100W)

Group Name	NO. of Animals	RETICULOCYTE %	
Control	11	4.0±	2.3
0.1ppm	17	9.0±	9.4
0.4ppm	14	6.3±	4.2
1.6ppm	18	6.0±	6.7

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

HEMATOLOGY (SUMMARY)
ALL ANIMALS (100W)

Group Name	NO. of Animals	WBC $10^3/\mu\ell$	Differential WBC (%) NEUTRO	LYMPHO	MONO	EOSINO	BASO	OTHER
Control	11	2.24± 1.36	39± 11	57± 10	1± 0	2± 2	0± 0	1± 1
0.1ppm	17	3.84± 3.42	35± 17	59± 17	2± 2	1± 1	0± 0	1± 1
0.4ppm	14	2.91± 1.37	41± 14	54± 15	2± 1	2± 1	0± 0	1± 1
1.6ppm	18	4.24± 5.88	34± 12	57± 17	2± 2	2± 1	0± 0	6± 19

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G1

BIOCHEMISTRY : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (94W)

Group Name	NO. of Animals	TOTAL PROTEIN g／dℓ	ALBUMIN g／dℓ	A/G RATIO	T-BILIRUBIN mg／dℓ	GLUCOSE mg／dℓ	T-CHOLESTEROL mg／dℓ	TRIGLYCERIDE mg／dℓ
Control	11	4.5± 0.7	2.0± 0.4	0.8± 0.2	0.02± 0.02	181± 71	193± 160	84± 52
0.1ppm	14	4.8± 0.6	2.1± 0.3	0.8± 0.2	0.03± 0.02	134± 71	145± 42	39± 30**
0.4ppm	14	4.9± 0.5	2.1± 0.2	0.8± 0.1	0.02± 0.01	180± 46	147± 63	62± 36
1.6ppm	15	4.5± 0.9	2.0± 0.4	0.8± 0.2	0.02± 0.01	141± 85	179± 106	46± 25*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (94W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dl	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	11	286± 140	53± 7	23± 21	207± 70	236± 113	0.2± 0.2	130± 204
0.1ppm	14	217± 75	117± 171	285± 782	938± 2145	234± 77	0.4± 0.2	159± 122*
0.4ppm	14	251± 82	70± 40	25± 14	199± 46	245± 133	0.2± 0.2	80± 30
1.6ppm	15	250± 126	176± 421	111± 312	329± 415	284± 170	0.2± 0.2	224± 265*

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (94W)

Group Name	NO. of Animals	UREA NITROGEN mg／dℓ		SODIUM mEq／ℓ		POTASSIUM mEq／ℓ		CHLORIDE mEq／ℓ		CALCIUM mg／dℓ		INORGANIC PHOSPHORUS mg／dℓ	
Control	11	67.4±	66.8	159±	4	4.7±	1.3	123±	5	9.4±	0.8	8.8±	4.9
0.1ppm	14	79.6±	68.5	159±	3	4.5±	1.0	122±	4	9.4±	0.6	10.0±	5.7
0.4ppm	14	59.5±	44.8	157±	3	4.3±	0.5	121±	5	9.5±	0.9	8.1±	4.2
1.6ppm	15	104.8±	82.7	159±	5	4.8±	1.3	121±	7	9.0±	1.1	12.4±	7.5

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE G2

BIOCHEMISTRY : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (100W)

Group Name	NO. of Animals	TOTAL PROTEIN g／dℓ	ALBUMIN g／dℓ	A/G RATIO	T-BILIRUBIN mg／dℓ	GLUCOSE mg／dℓ	T-CHOLESTEROL mg／dℓ	TRIGLYCERIDE mg／dℓ
Control	11	5.1± 0.4	2.4± 0.2	0.9± 0.2	0.03± 0.02	141± 46	108± 29	34± 26
0.1ppm	17	4.6± 0.8	2.4± 0.3	1.1± 0.2	0.05± 0.05	131± 50	90± 17	30± 10
0.4ppm	14	4.7± 1.0	2.2± 0.3	1.0± 0.2	0.04± 0.03	144± 46	88± 28	37± 17
1.6ppm	18	4.6± 0.8	2.3± 0.3	1.0± 0.2	0.05± 0.05	159± 59	93± 25	30± 13

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (100W)

Group Name	NO. of Animals	PHOSPHOLIPID mg/dℓ	AST U/L	ALT U/L	LDH U/L	ALP U/L	G-GTP U/L	CK U/L
Control	11	183± 63	76± 24	24± 10	210± 89	685± 433	0.4± 0.2	220± 253
0.1ppm	17	155± 35	97± 35	30± 14	343± 417	586± 429	0.4± 0.2	263± 268
0.4ppm	14	156± 46	144± 138	46± 50	976± 2646	597± 391	0.4± 0.2	244± 189
1.6ppm	18	159± 42	104± 145	61± 160	483± 1276	667± 297	0.6± 0.4	282± 362

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

BIOCHEMISTRY (SUMMARY)
ALL ANIMALS (100W)

Group Name	NO. of Animals	UREA NITROGEN mg/dℓ	SODIUM mEq/ℓ	POTASSIUM mEq/ℓ	CHLORIDE mEq/ℓ	CALCIUM mg/dℓ	INORGANIC PHOSPHORUS mg/dℓ
Control	11	65.5± 46.9	156± 2	3.9± 0.7	121± 4	10.3± 1.0	8.9± 2.7
0.1ppm	17	75.5± 75.0	158± 5	4.7± 1.4	123± 5	10.0± 0.8	10.4± 5.2
0.4ppm	14	48.6± 35.8	158± 4	4.1± 0.9	125± 7	9.8± 0.8	8.2± 2.2
1.6ppm	18	69.7± 62.4	158± 3	4.5± 1.8	124± 5	9.8± 0.6	9.1± 6.5

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE H1

URINALYSIS : MALE

STUDY NO. : 0817 URINALYSIS

ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]

MEASURE. TIME : 1

SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	16	0	6	3	2	3	1	1		0	4	3	4	5	0		16	0	0	0	0	0		12	3	1	0	0	0		14	0	1	0	1	
0.1ppm	19	0	13	2	2	1	0	1		0	5	1	8	5	0		19	0	0	0	0	0		17	2	0	0	0	0		19	0	0	0	0	
0.4ppm	14	0	7	7	0	0	0	0		0	4	6	2	1	1		14	0	0	0	0	0		9	4	1	0	0	0		14	0	0	0	0	
1.6ppm	23	0	14	5	3	1	0	0		0	2	5	7	9	0		23	0	0	0	0	0		18	3	2	0	0	0		23	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0817 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 1
SEX : MALE REPORT TYPE : A1

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	16	16	0	0	0	0	
0.1ppm	19	19	0	0	0	0	
0.4ppm	14	14	0	0	0	0	
1.6ppm	23	23	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE H2

URINALYSIS : FEMALE

STUDY NO. : 0817 URINALYSIS

ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]

MEASURE. TIME : 2

SEX : FEMALE REPORT TYPE : A2

Group Name	NO. of Animals	pH 5.0	6.0	6.5	7.0	7.5	8.0	8.5	CHI	Protein −	±	+	2+	3+	4+	CHI	Glucose −	±	+	2+	3+	4+	CHI	Ketone body −	±	+	2+	3+	4+	CHI	Occult blood −	±	+	2+	3+	CHI
Control	16	0	10	6	0	0	0	0		7	1	3	2	3	0		16	0	0	0	0	0		14	1	1	0	0	0		16	0	0	0	0	
0.1ppm	21	0	12	5	1	2	1	0		5	5	4	6	1	0		21	0	0	0	0	0		18	2	1	0	0	0		21	0	0	0	0	
0.4ppm	18	0	9	4	1	3	1	0		5	6	2	4	1	0		18	0	0	0	0	0		16	0	2	0	0	0		16	0	0	1	1	
1.6ppm	25	0	12	4	5	1	2	1		3	2	5	7	8	0		25	0	0	0	0	0		17	2	6	0	0	0		23	0	1	0	1	

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

STUDY NO. : 0817 URINALYSIS
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
MEASURE. TIME : 2
SEX : FEMALE REPORT TYPE : A2

Group Name	NO. of Animals	Urobilinogen ±	+	2+	3+	4+	CHI
Control	16	16	0	0	0	0	
0.1ppm	21	21	0	0	0	0	
0.4ppm	18	18	0	0	0	0	
1.6ppm	25	25	0	0	0	0	

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of CHI SQUARE

TABLE I 1

GROSS FINDINGS : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0- 94W)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.1ppm 50	(%)	0.4ppm 50	(%)	1.6ppm 50	(%)
skin/app	nodule		1	(2)	0	(0)	0	(0)	0	(0)
	erosion		1	(2)	3	(6)	3	(6)	0	(0)
	crust		1	(2)	0	(0)	0	(0)	0	(0)
subcutis	edema		5	(10)	3	(6)	5	(10)	7	(14)
	mass		2	(4)	0	(0)	1	(2)	0	(0)
lung	red zone		1	(2)	0	(0)	2	(4)	1	(2)
	nodule		1	(2)	0	(0)	2	(4)	1	(2)
lymph node	enlarged		4	(8)	5	(10)	2	(4)	5	(10)
spleen	enlarged		1	(2)	1	(2)	3	(6)	0	(0)
	black zone		0	(0)	1	(2)	2	(4)	2	(4)
	nodule		0	(0)	0	(0)	1	(2)	0	(0)
	accentuation of white pulp		1	(2)	0	(0)	0	(0)	0	(0)
heart	white zone		0	(0)	0	(0)	0	(0)	1	(2)
stomach	forestomach:nodule		0	(0)	0	(0)	1	(2)	0	(0)
	glandular stomach:thick		5	(10)	3	(6)	7	(14)	0	(0)
small intes	white zone		0	(0)	0	(0)	1	(2)	0	(0)
	nodule		1	(2)	1	(2)	0	(0)	1	(2)
cecum	white zone		0	(0)	0	(0)	1	(2)	0	(0)
liver	enlarged		0	(0)	1	(2)	0	(0)	0	(0)
	white zone		2	(4)	1	(2)	1	(2)	1	(2)
	red zone		0	(0)	2	(4)	1	(2)	1	(2)
	nodule		3	(6)	3	(6)	7	(14)	7	(14)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.1ppm 50	(%)	0.4ppm 50	(%)	1.6ppm 50	(%)
liver	deformed		0	(0)	1	(2)	0	(0)	0	(0)
kidney	enlarged		1	(2)	3	(6)	4	(8)	1	(2)
	small		0	(0)	0	(0)	1	(2)	0	(0)
	pale		0	(0)	1	(2)	0	(0)	0	(0)
	white zone		0	(0)	1	(2)	1	(2)	0	(0)
	nodule		0	(0)	1	(2)	0	(0)	0	(0)
	cyst		7	(14)	4	(8)	2	(4)	6	(12)
	deformed		35	(70)	26	(52)	21	(42)	30	(60)
	hydronephrosis		5	(10)	8	(16)	6	(12)	5	(10)
urin bladd	white		0	(0)	1	(2)	0	(0)	0	(0)
	urine:marked retention		3	(6)	6	(12)	4	(8)	2	(4)
	urine:red		0	(0)	0	(0)	0	(0)	1	(2)
testis	enlarged		0	(0)	1	(2)	0	(0)	0	(0)
	small		0	(0)	0	(0)	0	(0)	1	(2)
epididymis	nodule		1	(2)	0	(0)	0	(0)	0	(0)
prostate	red zone		0	(0)	1	(2)	0	(0)	0	(0)
prep/cli gl	enlarged		1	(2)	0	(0)	0	(0)	0	(0)
	nodule		1	(2)	0	(0)	3	(6)	0	(0)
Harder gl	enlarged		0	(0)	0	(0)	1	(2)	1	(2)
	nodule		1	(2)	0	(0)	1	(2)	0	(0)
peritoneum	nodule		1	(2)	1	(2)	0	(0)	0	(0)
	thick		1	(2)	0	(0)	0	(0)	0	(0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	0.1ppm 50 (%)	0.4ppm 50 (%)	1.6ppm 50 (%)
abdominal c	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)
	ascites		7 (14)	7 (14)	5 (10)	5 (10)
thoracic ca	pleural fluid		16 (32)	12 (24)	10 (20)	19 (38)
other	tail:nodule		1 (2)	0 (0)	0 (0)	0 (0)
	hindlimb:nodule		0 (0)	0 (0)	1 (2)	0 (0)
whole body	anemic		3 (6)	0 (0)	1 (2)	0 (0)

TABLE I 2

GROSS FINDINGS : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2
SEX : FEMALE

GROSS FINDINGS (SUMMARY)
ALL ANIMALS (0-100W)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	0.1ppm 50 (%)	0.4ppm 50 (%)	1.6ppm 50 (%)
skin/app	crust		0 (0)	0 (0)	1 (2)	0 (0)
subcutis	edema		5 (10)	7 (14)	4 (8)	6 (12)
	mass		4 (8)	2 (4)	3 (6)	1 (2)
lung	red		0 (0)	1 (2)	0 (0)	0 (0)
	red zone		1 (2)	1 (2)	0 (0)	1 (2)
	nodule		2 (4)	3 (6)	0 (0)	2 (4)
lymph node	enlarged		14 (28)	13 (26)	11 (22)	18 (36)
thymus	enlarged		0 (0)	0 (0)	0 (0)	1 (2)
	atrophic		0 (0)	1 (2)	0 (0)	0 (0)
spleen	enlarged		8 (16)	9 (18)	13 (26)	14 (28)
	white zone		2 (4)	0 (0)	0 (0)	0 (0)
	black zone		0 (0)	0 (0)	1 (2)	0 (0)
heart	white		0 (0)	1 (2)	0 (0)	0 (0)
	white zone		0 (0)	1 (2)	0 (0)	0 (0)
	red zone		0 (0)	1 (2)	0 (0)	0 (0)
tongue	nodule		1 (2)	0 (0)	0 (0)	0 (0)
stomach	forestomach:nodule		0 (0)	1 (2)	0 (0)	0 (0)
	glandular stomach:nodule		0 (0)	0 (0)	1 (2)	0 (0)
	glandular stomach:thick		0 (0)	0 (0)	1 (2)	3 (6)
small intes	nodule		1 (2)	1 (2)	0 (0)	1 (2)
anus	nodule		0 (0)	0 (0)	1 (2)	0 (0)
large intes	nodule		0 (0)	0 (0)	1 (2)	0 (0)

Organ	Findings	Group Name / NO. of Animals	Control 50 (%)	0.1ppm 50 (%)	0.4ppm 50 (%)	1.6ppm 50 (%)
liver	enlarged		4 (8)	1 (2)	3 (6)	5 (10)
	white zone		3 (6)	5 (10)	4 (8)	5 (10)
	red zone		0 (0)	2 (4)	0 (0)	0 (0)
	nodule		7 (14)	3 (6)	5 (10)	4 (8)
pancreas	nodule		0 (0)	1 (2)	0 (0)	0 (0)
kidney	enlarged		0 (0)	2 (4)	0 (0)	2 (4)
	atrophic		0 (0)	0 (0)	0 (0)	1 (2)
	small		0 (0)	1 (2)	1 (2)	2 (4)
	pale		0 (0)	0 (0)	1 (2)	0 (0)
	cyst		3 (6)	1 (2)	0 (0)	2 (4)
	deformed		31 (62)	31 (62)	31 (62)	22 (44)
	hydronephrosis		7 (14)	6 (12)	6 (12)	6 (12)
urin bladd	urine:marked retention		3 (6)	0 (0)	0 (0)	2 (4)
pituitary	enlarged		2 (4)	2 (4)	0 (0)	0 (0)
	red zone		2 (4)	0 (0)	1 (2)	0 (0)
ovary	enlarged		6 (12)	11 (22)	9 (18)	9 (18)
	nodule		0 (0)	1 (2)	0 (0)	0 (0)
	cyst		10 (20)	13 (26)	13 (26)	8 (16)
uterus	nodule		7 (14)	12 (24)	11 (22)	7 (14)
	cyst		0 (0)	1 (2)	0 (0)	0 (0)
	dilated lumen		0 (0)	2 (4)	0 (0)	1 (2)
vagina	nodule		0 (0)	1 (2)	1 (2)	0 (0)

Organ	Findings	Group Name / NO. of Animals	Control 50	(%)	0.1ppm 50	(%)	0.4ppm 50	(%)	1.6ppm 50	(%)
periph nerv	nodule		0	(0)	0	(0)	1	(2)	0	(0)
Harder gl	enlarged		1	(2)	0	(0)	0	(0)	0	(0)
muscle	nodule		1	(2)	0	(0)	0	(0)	0	(0)
mediastinum	mass		0	(0)	0	(0)	0	(0)	1	(2)
peritoneum	nodule		0	(0)	1	(2)	1	(2)	3	(6)
	thick		0	(0)	0	(0)	0	(0)	1	(2)
abdominal c	hemorrhage		0	(0)	0	(0)	0	(0)	2	(4)
	ascites		7	(14)	12	(24)	8	(16)	10	(20)
thoracic ca	hemorrhage		0	(0)	0	(0)	0	(0)	1	(2)
	pleural fluid		17	(34)	16	(32)	13	(26)	14	(28)
whole body	anemic		0	(0)	0	(0)	2	(4)	0	(0)

TABLE J1

ORGAN WEIGHT, ABSOLUTE : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (94W)

Group Name	NO. of Animals	Body Weight	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	11	34.0± 7.6	0.012± 0.002	0.223± 0.039	0.226± 0.031	0.180± 0.013	0.663± 0.092
0.1ppm	15	29.8± 3.2	0.013± 0.002	0.227± 0.063	0.229± 0.046	0.184± 0.015	1.578± 2.341
0.4ppm	14	31.7± 5.5	0.013± 0.002	0.225± 0.036	0.227± 0.047	0.190± 0.034	1.401± 2.365
1.6ppm	15	27.6± 4.4	0.013± 0.004	0.230± 0.043	0.210± 0.030	0.188± 0.023	0.816± 0.782

Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (94W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	11	0.104± 0.050	1.571± 0.200	0.478± 0.020
0.1ppm	15	0.119± 0.075	1.423± 0.190	0.468± 0.026
0.4ppm	14	0.098± 0.044	1.509± 0.160	0.471± 0.026
1.6ppm	15	0.084± 0.034	1.315± 0.160**	0.462± 0.026

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE J2

ORGAN WEIGHT, ABSOLUTE : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (100W)

Group Name	NO. of Animals	Body Weight	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	11	25.0± 1.8	0.016± 0.004	0.242± 0.559	0.191± 0.042	0.196± 0.027	0.632± 0.407
0.1ppm	17	26.7± 3.7	0.017± 0.004	0.186± 0.460	0.188± 0.044	0.198± 0.020	0.455± 0.072
0.4ppm	14	28.3± 3.0*	0.017± 0.004	0.473± 1.421	0.188± 0.031	0.209± 0.032	0.515± 0.099
1.6ppm	19	25.3± 1.8	0.016± 0.003	0.058± 0.046	0.198± 0.044	0.207± 0.036	0.739± 0.876

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2
SEX : FEMALE
UNIT: g

ORGAN WEIGHT:ABSOLUTE (SUMMARY)
SURVIVAL ANIMALS (100W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	11	0.165± 0.113	1.361± 0.240	0.490± 0.027
0.1ppm	17	0.212± 0.214	1.480± 0.348	0.484± 0.027
0.4ppm	14	0.223± 0.143	1.653± 0.639	0.497± 0.020
1.6ppm	19	0.266± 0.551	1.489± 0.626	0.472± 0.029

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K1

ORGAN WEIGHT, RELATIVE : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (94W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	TESTES	HEART	LUNGS	KIDNEYS
Control	11	34.0± 7.6	0.037± 0.007	0.678± 0.169	0.695± 0.182	0.549± 0.094	2.022± 0.484
0.1ppm	15	29.8± 3.2	0.043± 0.009	0.763± 0.190	0.777± 0.180	0.620± 0.071	4.855± 6.492
0.4ppm	14	31.7± 5.5	0.040± 0.008	0.722± 0.133	0.741± 0.230	0.615± 0.161	3.985± 5.615
1.6ppm	15	27.6± 4.4	0.049± 0.012**	0.847± 0.172	0.778± 0.150	0.690± 0.097**	2.840± 2.127

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (94W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	11	0.314± 0.133	4.776± 0.970	1.464± 0.294
0.1ppm	15	0.406± 0.276	4.797± 0.675	1.581± 0.159
0.4ppm	14	0.319± 0.161	4.842± 0.664	1.520± 0.230
1.6ppm	15	0.313± 0.147	4.829± 0.694	1.709± 0.275

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE K2

ORGAN WEIGHT, RELATIVE : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (100W)

Group Name	NO. of Animals	Body Weight (g)	ADRENALS	OVARIES	HEART	LUNGS	KIDNEYS
Control	11	25.0± 1.8	0.064± 0.013	0.948± 2.163	0.762± 0.158	0.788± 0.125	2.567± 1.778
0.1ppm	17	26.7± 3.7	0.063± 0.016	0.698± 1.734	0.724± 0.239	0.748± 0.095	1.720± 0.276
0.4ppm	14	28.3± 3.0*	0.062± 0.016	1.511± 4.417	0.668± 0.099	0.744± 0.132	1.822± 0.321
1.6ppm	19	25.3± 1.8	0.063± 0.013	0.231± 0.182	0.781± 0.146	0.817± 0.116	2.827± 3.071

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2
SEX : FEMALE
UNIT: %

ORGAN WEIGHT:RELATIVE (SUMMARY)
SURVIVAL ANIMALS (100W)

Group Name	NO. of Animals	SPLEEN	LIVER	BRAIN
Control	11	0.652± 0.446	5.416± 0.695	1.961± 0.083
0.1ppm	17	0.767± 0.702	5.508± 0.789	1.840± 0.233
0.4ppm	14	0.777± 0.465	5.773± 1.753	1.775± 0.192
1.6ppm	19	0.993± 1.921	5.817± 2.066	1.873± 0.172

Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Dunnett

TABLE L1

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : MALE

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		0 (0%)	0 (0%)	2 (4%)	1 (2%)
	hemangioma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	bronchiolar-alveolar carcinoma		1 (2%)	0 (0%)	1 (2%)	1 (2%)
{Hematopoietic system}						
lymph node			<50>	<50>	<50>	<50>
	malignant lymphoma		1 (2%)	3 (6%)	2 (4%)	4 (8%)
	mastcytoma:malignant		0 (0%)	1 (2%)	1 (2%)	0 (0%)
spleen			<50>	<50>	<50>	<50>
	mastcytoma:benign		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	mastcytoma:malignant		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Digestive system}						
tooth			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Digestive system}						
stomach			<50>	<50>	<50>	<50>
	squamous cell papilloma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
small intes			<50>	<50>	<50>	<50>
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
liver			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	4 (8%)	2 (4%)	1 (2%)
	hepatocellular adenoma		4 (8%)	1 (2%)	3 (6%)	3 (6%)
	histiocytic sarcoma		0 (0%)	2 (4%)	0 (0%)	2 (4%)
	hepatocellular carcinoma		0 (0%)	1 (2%)	2 (4%)	2 (4%)
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	adenoma		1 (2%)	0 (0%)	2 (4%)	1 (2%)
{Body cavities}						
peritoneum			<50>	<50>	<50>	<50>
	leiomyosarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	histiocytic sarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE L2

HISTOPATHOLOGICAL FINDINGS :

NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name	Control	0.1ppm	0.4ppm	1.6ppm
		No. of animals on Study	50	50	50	50
{Integumentary system/appandage}						
subcutis			<50>	<50>	<50>	<50>
	fibrosarcoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
	liposarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	leiomyosarcoma		1 (2%)	0 (0%)	1 (2%)	1 (2%)
	histiocytic sarcoma		1 (2%)	0 (0%)	1 (2%)	0 (0%)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	0 (0%)	0 (0%)	16 (32%)
lung			<50>	<50>	<50>	<50>
	bronchiolar-alveolar adenoma		1 (2%)	3 (6%)	0 (0%)	0 (0%)
	bronchiolar-alveolar carcinoma		1 (2%)	0 (0%)	0 (0%)	1 (2%)
{Hematopoietic system}						
lymph node			<50>	<50>	<50>	<50>
	malignant lymphoma		12 (24%)	8 (16%)	6 (12%)	17 (34%)
spleen			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
	malignant lymphoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Hematopoietic system}						
spleen			<50>	<50>	<50>	<50>
	mastcytoma:malignant		0 (0%)	0 (0%)	2 (4%)	0 (0%)
{Digestive system}						
tongue			<50>	<50>	<50>	<50>
	squamous cell papilloma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
large intes			<50>	<50>	<50>	<50>
	leiomyoma		0 (0%)	0 (0%)	1 (2%)	0 (0%)
liver			<50>	<50>	<50>	<50>
	hemangioma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	hepatocellular adenoma		2 (4%)	2 (4%)	0 (0%)	0 (0%)
	histiocytic sarcoma		0 (0%)	2 (4%)	0 (0%)	3 (6%)
	hemangiosarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	hepatocellular carcinoma		0 (0%)	1 (2%)	0 (0%)	1 (2%)
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	adenoma		0 (0%)	1 (2%)	1 (2%)	0 (0%)
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	cystadenoma		0 (0%)	1 (2%)	2 (4%)	1 (2%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

Organ	Findings	Group Name / No. of animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Reproductive system}						
uterus			<50>	<50>	<50>	<50>
	endometrial stromal polyp		1 (2%)	1 (2%)	2 (4%)	3 (6%)
	histiocytic sarcoma		6 (12%)	13 (26%)	14 (28%)	6 (12%)
vagina			<50>	<50>	<50>	<50>
	histiocytic sarcoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
mammary gl			<50>	<50>	<50>	<50>
	adenoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
	adenocarcinoma		0 (0%)	1 (2%)	0 (0%)	0 (0%)
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	adenoma		1 (2%)	0 (0%)	0 (0%)	2 (4%)
	histiocytic sarcoma		0 (0%)	0 (0%)	0 (0%)	1 (2%)
{Musculoskeletal system}						
bone			<50>	<50>	<50>	<50>
	osteosarcoma		1 (2%)	0 (0%)	0 (0%)	0 (0%)
{Body cavities}						
peritoneum			<50>	<50>	<50>	<50>
	hemangioma		0 (0%)	1 (2%)	0 (0%)	0 (0%)

< a > a : Number of animals examined at the site
b (c) b : Number of animals with neoplasm c : b / a * 100

TABLE M1

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : MALE

Group Name	Control	100ppb	400ppb	1600ppb
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma, bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	0/50(0.0)	3/50(6.0)	2/50(4.0)
Adjusted rates(b)	3.45	0.0	14.29	5.88
Terminal rates(c)	0/11(0.0)	0/15(0.0)	2/14(14.3)	0/15(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.2854			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.4166			
Fisher Exact test(e)		P = 0.5000	P = 0.3087	P = 0.5000
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	3/50(6.0)	2/50(4.0)	4/50(8.0)
Adjusted rates(b)	9.09	6.67	7.14	6.67
Terminal rates(c)	1/11(9.1)	1/15(6.7)	1/14(7.1)	1/15(6.7)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1833			
Prevalence method(d)	P = 0.3936			
Combined analysis(d)	P = 0.2172			
Cochran-Armitage test(e)	P = 0.2524			
Fisher Exact test(e)		P = 0.3087	P = 0.5000	P = 0.1811
	SITE : liver			
	TUMOR : hemangioma			
Tumor rate				
Overall rates(a)	0/50(0.0)	4/50(8.0)	2/50(4.0)	1/50(2.0)
Adjusted rates(b)	0.0	25.00	7.14	3.57
Terminal rates(c)	0/11(0.0)	3/15(20.0)	1/14(7.1)	0/15(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.3836			
Prevalence method(d)	P = 0.7303			
Combined analysis(d)	P = 0.7514			
Cochran-Armitage test(e)	P = 0.5976			
Fisher Exact test(e)		P = 0.0587	P = 0.2475	P = 0.5000

Group Name	Control	100ppb	400ppb	1600ppb
SITE : liver				
TUMOR : hepatocellular adenoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	1/50(2.0)	3/50(6.0)	3/50(6.0)
Adjusted rates(b)	10.53	6.67	8.82	13.04
Terminal rates(c)	0/11(0.0)	1/15(6.7)	1/14(7.1)	1/15(6.7)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.5380			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.8744			
Fisher Exact test(e)		P = 0.1811	P = 0.5000	P = 0.5000
SITE : liver				
TUMOR : hepatocellular adenoma, hepatocellular carcinoma				
Tumor rate				
Overall rates(a)	4/50(8.0)	2/50(4.0)	5/50(10.0)	5/50(10.0)
Adjusted rates(b)	10.53	6.67	13.16	13.04
Terminal rates(c)	0/11(0.0)	1/15(6.7)	1/14(7.1)	1/15(6.7)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.3263			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.4620			
Fisher Exact test(e)		P = 0.3389	P = 0.5000	P = 0.5000

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference ; * : $P \leqq 0.05$ ** : $P \leqq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

TABLE M2

NEOPLASTIC LESIONS-INCIDENCE

AND STATISTICAL ANALYSIS : FEMALE

Group Name	Control	100ppb	400ppb	1600ppb
	SITE : nasal cavity			
	TUMOR : adenoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	0/50(0.0)	0/50(0.0)	16/50(32.0)
Adjusted rates(b)	0.0	0.0	0.0	46.15
Terminal rates(c)	0/11(0.0)	0/18(0.0)	0/14(0.0)	8/19(42.1)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P < 0.0001**?			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P < 0.0001**			
Fisher Exact test(e)		P = N.C.	P = N.C.	P < 0.0001**
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma			
Tumor rate				
Overall rates(a)	1/50(2.0)	3/50(6.0)	0/50(0.0)	0/50(0.0)
Adjusted rates(b)	4.35	11.11	0.0	0.0
Terminal rates(c)	0/11(0.0)	2/18(11.1)	0/14(0.0)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.9521			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.1541			
Fisher Exact test(e)		P = 0.3087	P = 0.5000	P = 0.5000
	SITE : lung			
	TUMOR : bronchiolar-alveolar adenoma,bronchiolar-alveolar carcinoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	3/50(6.0)	0/50(0.0)	1/50(2.0)
Adjusted rates(b)	9.09	11.11	0.0	4.17
Terminal rates(c)	1/11(9.1)	2/18(11.1)	0/14(0.0)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.8269			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.4166			
Fisher Exact test(e)		P = 0.5000	P = 0.2475	P = 0.5000

Group Name	Control	100ppb	400ppb	1600ppb
	SITE : lymph node			
	TUMOR : malignant lymphoma			
Tumor rate				
Overall rates(a)	12/50(24.0)	8/50(16.0)	6/50(12.0)	17/50(34.0)
Adjusted rates(b)	28.57	27.78	35.71	47.37
Terminal rates(c)	3/11(27.3)	5/18(27.8)	5/14(35.7)	9/19(47.4)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2189			
Prevalence method(d)	P = 0.1017			
Combined analysis(d)	P = 0.0727			
Cochran-Armitage test(e)	P = 0.0347*			
Fisher Exact test(e)		P = 0.2270	P = 0.0961	P = 0.1891
	SITE : liver			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	0/50(0.0)	2/50(4.0)	0/50(0.0)	3/50(6.0)
Adjusted rates(b)	0.0	0.0	0.0	5.26
Terminal rates(c)	0/11(0.0)	0/18(0.0)	0/14(0.0)	1/19(5.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.2068			
Prevalence method(d)	P = 0.2110			
Combined analysis(d)	P = 0.0923			
Cochran-Armitage test(e)	P = 0.0917			
Fisher Exact test(e)		P = 0.2475	P = N.C.	P = 0.1212
	SITE : liver			
	TUMOR : hepatocellular adenoma,hepatocellular carcinoma			
Tumor rate				
Overall rates(a)	2/50(4.0)	3/50(6.0)	0/50(0.0)	1/50(2.0)
Adjusted rates(b)	9.09	14.29	0.0	0.0
Terminal rates(c)	1/11(9.1)	2/18(11.1)	0/14(0.0)	0/19(0.0)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.1743			
Prevalence method(d)	P = 0.9823			
Combined analysis(d)	P = 0.8389			
Cochran-Armitage test(e)	P = 0.4166			
Fisher Exact test(e)		P = 0.5000	P = 0.2475	P = 0.5000

Group Name	Control	100ppb	400ppb	1600ppb
	SITE : uterus			
	TUMOR : endometrial stromal polyp			
Tumor rate				
Overall rates(a)	1/50(2.0)	1/50(2.0)	2/50(4.0)	3/50(6.0)
Adjusted rates(b)	9.09	2.56	6.90	12.50
Terminal rates(c)	1/11(9.1)	0/18(0.0)	0/14(0.0)	2/19(10.5)
Statistical analysis				
Peto test				
Standard method(d)	P = ------			
Prevalence method(d)	P = 0.1457			
Combined analysis(d)	P = ------			
Cochran-Armitage test(e)	P = 0.2219			
Fisher Exact test(e)		P = 0.7525	P = 0.5000	P = 0.3087
	SITE : uterus			
	TUMOR : histiocytic sarcoma			
Tumor rate				
Overall rates(a)	6/50(12.0)	13/50(26.0)	14/50(28.0)	6/50(12.0)
Adjusted rates(b)	3.13	30.00	23.53	5.26
Terminal rates(c)	0/11(0.0)	5/18(27.8)	3/14(21.4)	1/19(5.3)
Statistical analysis				
Peto test				
Standard method(d)	P = 0.6420			
Prevalence method(d)	P = 0.9602			
Combined analysis(d)	P = 0.9192			
Cochran-Armitage test(e)	P = 0.2661			
Fisher Exact test(e)		P = 0.0624	P = 0.0392*	P = 0.6202

(a): Number of tumor-bearing animals/number of animals examined at the site.
(b): Kaplan-Meier estimated tumor incidence at the end of the study after adjusting for intercurrent mortality.
(c): Observed tumor incidence at terminal kill.
(d): Beneath the control incidence are the P-values associated with the trend test.
Standard method : Death analysis
Prevalence method : Incidental tumor test
Combined analysis : Death analysis + Incidental tumor test
(e): The Cochran-Armitage and Fisher exact test compare directly the overall incidence rates.
? : The conditional probabilities of the largest and smallest possible out comes can not estimated or this P-value is beyond the estimated P-value.
------ : There is no data which should be statistical analysis.
Significant difference : * : $P \leqq 0.05$ ** : $P \leqq 0.01$
N.C. :Statistical value cannot be calculated and was not significant.

TABLE N1

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj MALE MICE

TABLE N1 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj MALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Nasal cavity	499			
Adenoma		1	0.2	0 - 2

11 carcinogenicity studies examined in Japan Bioassay Research Center were used.
Study No. : 0458, 0515, 0561, 0580, 0611, 0613, 0676, 0705, 0732, 0754, 0775

TABLE N2

HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj FEMALE MICE

TABLE N2 HISTORICAL CONTROL DATA OF SELECTED NEOPLASTIC LESIONS IN JAPAN BIOASSAY RESEARCH CENTER : B6D2F1/Crlj FEMALE MICE

Organs Tumors	No. of animals examined	No. of animals bearing tumor	Incidence (%)	Min. - Max. (%)
Nasal cavity	500			
Adenoma		0	0	0 - 0
Lymph node	500			
Malignant lymphoma		169	33.8	28 - 46
Uterus	500			
Histiocytic sarcoma		114	22.8	18 - 34

11 carcinogenicity studies examined in Japan Bioassay Research Center were used.
Study No. : 0458, 0515, 0561, 0580, 0611, 0613, 0676, 0705, 0732, 0754, 0775

TABLE O1

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : MALE

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Integumentary system/appandage]																		
skin/app			<50>				<50>				<50>				<50>			
	ulcer		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	erosion		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	squamous cell hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	scab		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	epidermal cyst		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	xanthogranuloma		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
subcutis			<50>				<50>				<50>				<50>			
	inflammation		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	epidermal cyst		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	exudate		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	27 (54)	8 (16)	0 (0)	0 (0) **
	eosinophilic change:olfactory epithelium		7 (14)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium		4 (8)	1 (2)	0 (0)	0 (0)	7 (14)	2 (4)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	10 (20)	24 (48)	0 (0)	0 (0) **
	inflammation:foreign body		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	inflammation:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	22 (44)	2 (4)	0 (0)	0 (0) **
	respiratory metaplasia:olfactory epithelium		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	27 (54)	3 (6)	0 (0)	0 (0) **
	respiratory metaplasia:gland		13 (26)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	16 (32)	1 (2)	0 (0)	0 (0)	21 (42)	13 (26)	0 (0)	0 (0) **
	squamous cell metaplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	27 (54)	0 (0)	0 (0)	0 (0) **

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	atrophy:turbinate		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 * (0)
	hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 ** (0)
	septal perforation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	regeneration:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	28 (56)	20 (40)	0 (0)	0 ** (0)
	atrophy:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	17 (34)	0 (0)	0 (0)	0 ** (0)
	hyperplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	10 (20)	5 (10)	0 (0)	0 ** (0)
	adhesion:turbinate		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 ** (0)
nasopharynx			<50>				<50>				<50>				<50>			
	eosinophilic change		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Respiratory system}																		
lung			<50>				<50>				<50>				<50>			
	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	edema		3 (6)	3 (6)	0 (0)	0 (0)	5 (10)	3 (6)	0 (0)	0 (0)	3 (6)	3 (6)	0 (0)	0 (0)	6 (12)	2 (4)	0 (0)	0 (0)
	thrombus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		10 (20)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)
	inflammatory infiltration		2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	granulomatous inflammation		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia		5 (10)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
	accumulation:macrophage		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Hematopoietic system}																		
bone marrow		<50>																
	increased hematopoiesis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	granulopoiesis:increased		6 (12)	2 (4)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
lymph node		<50>																
	lymphadenitis		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)
spleen		<50>																
	deposit of melanin		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis		25 (50)	2 (4)	0 (0)	0 (0)	25 (50)	4 (8)	0 (0)	0 (0)	21 (42)	4 (8)	0 (0)	0 (0)	22 (44)	4 (8)	0 (0)	0 (0)
	follicular hyperplasia		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
{Circulatory system}																		
heart		<50>																
	thrombus		1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Circulatory system}																		
heart			<50>				<50>				<50>				<50>			
	necrosis:focal		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		18 (36)	14 (28)	0 (0)	0 (0)	17 (34)	15 (30)	0 (0)	0 (0)	14 (28)	17 (34)	0 (0)	0 (0)	15 (30)	19 (38)	0 (0)	0 (0)
	subendocardial fibrosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	arteritis		2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)
{Digestive system}																		
tooth			<50>				<50>				<50>				<50>			
	dysplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
tongue			<50>				<50>				<50>				<50>			
	arteritis		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Digestive system}																		
stomach		<50>					<50>				<50>				<50>			
	deposit of amyloid		45 (90)	1 (2)	0 (0)	0 (0)	43 (86)	2 (4)	0 (0)	0 (0)	38 (76)	0 (0)	0 (0)	0 (0)	48 (96)	2 (4)	0 (0)	0 (0)
	arteritis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	hyperkeratosis:forestomach		29 (58)	12 (24)	0 (0)	0 (0)	26 (52)	15 (30)	0 (0)	0 (0)	21 (42)	16 (32)	0 (0)	0 (0)	31 (62)	10 (20)	0 (0)	0 (0)
	hyperplasia:glandular stomach		6 (12)	40 (80)	1 (2)	0 (0)	8 (16)	41 (82)	0 (0)	0 (0)	7 (14)	38 (76)	1 (2)	0 (0)	9 (18)	39 (78)	0 (0)	0 (0)
small intes		<50>					<50>				<50>				<50>			
	hemorrhage		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		5 (10)	40 (80)	3 (6)	0 (0)	2 (4)	45 (90)	0 (0)	0 (0)	1 (2)	45 (90)	0 (0)	0 (0)	1 (2)	44 (88)	3 (6)	0 (0)
large intes		<50>					<50>				<50>				<50>			
	deposit of amyloid		11 (22)	0 (0)	0 (0)	0 (0)	15 (30)	0 (0)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 (0)	18 (36)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Digestive system}																		
liver			<50>				<50>				<50>				<50>			
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	necrosis:focal		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	deposit of amyloid		27 (54)	0 (0)	0 (0)	0 (0)	27 (54)	0 (0)	0 (0)	0 (0)	29 (58)	0 (0)	0 (0)	0 (0)	29 (58)	0 (0)	0 (0)	0 (0)
	granulomatous inflammation		0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory cell nest		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	acidophilic cell focus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	basophilic cell focus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
{Urinary system}																		
kidney			<50>				<50>				<50>				<50>			
	angiectasis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>	1	4	0	0	3	1	0	0	1	0	0	0	3	6	0	0
	cyst		(2)	(8)	(0)	(0)	(6)	(2)	(0)	(0)	(2)	(0)	(0)	(0)	(6)	(12)	(0)	(0)
	hyaline droplet		0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of amyloid		3	36	1	0	7	31	1	0	4	32	1	0	3	38	2	0
			(6)	(72)	(2)	(0)	(14)	(62)	(2)	(0)	(8)	(64)	(2)	(0)	(6)	(76)	(4)	(0)
	inflammatory infiltration		0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	lymphocytic infiltration		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	papillomatous polyp		1	2	0	0	3	1	0	0	1	1	1	0	2	3	1	0
			(2)	(4)	(0)	(0)	(6)	(2)	(0)	(0)	(2)	(2)	(2)	(0)	(4)	(6)	(2)	(0)
	arteritis		0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
	hydronephrosis		2	3	3	0	1	5	3	0	1	2	5	0	1	2	3	0
			(4)	(6)	(6)	(0)	(2)	(10)	(6)	(0)	(2)	(4)	(10)	(0)	(2)	(4)	(6)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Urinary system}																		
kidney			<50>				<50>				<50>				<50>			
	pyelonephritis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	papillary necrosis		4 (8)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)
	regeneration:proximal tubule		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	nephrosclerosis		1 (2)	30 (60)	2 (4)	0 (0)	5 (10)	29 (58)	0 (0)	0 (0)	3 (6)	26 (52)	1 (2)	0 (0)	3 (6)	32 (64)	4 (8)	0 (0)
urin bladd			<50>				<50>				<50>				<50>			
	dilatation		0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	1 (2)	2 (4)	0 (0)	0 (0)
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	simple hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
urethra			<50>				<50>				<50>				<50>			
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	1 (2)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Endocrine system}																		
pituitary			<49>				<50>				<50>				<50>			
	cyst		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	Rathke pouch		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
adrenal			<50>				<50>				<50>				<50>			
	deposit of amyloid		6 (12)	23 (46)	16 (32)	0 (0)	7 (14)	21 (42)	19 (38)	0 (0)	10 (20)	23 (46)	15 (30)	0 (0)	5 (10)	27 (54)	14 (28)	0 (0)
	spindle-cell hyperplasia		21 (42)	2 (4)	0 (0)	0 (0)	23 (46)	1 (2)	0 (0)	0 (0)	30 (60)	2 (4)	0 (0)	0 (0)	25 (50)	0 (0)	0 (0)	0 (0)
	focal hypertrophy:cortex		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Reproductive system}																		
testis			<50>				<50>				<50>				<50>			
	atrophy		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Reproductive system}																		
testis		<50>					<50>				<50>				<50>			
	edema		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
	mineralization		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	spermatogenic granuloma		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
epididymis		<50>					<50>				<50>				<50>			
	spermatogenic granuloma		3 (6)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
prostate		<50>					<50>				<50>				<50>			
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
prep/cli gl		<50>					<50>				<50>				<50>			
	duct ectasia		2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name	Control				0.1ppm				0.4ppm				1.6ppm			
		No. of Animals on Study	50				50				50				50			
		Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Nervous system}																		
brain			<50>				<50>				<50>				<50>			
	mineralization		16	0	0	0	14	0	0	0	18	0	0	0	13	0	0	0
			(32)	(0)	(0)	(0)	(28)	(0)	(0)	(0)	(36)	(0)	(0)	(0)	(26)	(0)	(0)	(0)
	gliosis		1	0	0	0	2	0	0	0	0	0	0	0	2	0	0	0
			(2)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)
{Special sense organs/appendage}																		
Harder gl			<50>				<50>				<50>				<50>			
	deposit of amyloid		0	0	0	0	0	2	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	lymphocytic infiltration		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE O2

HISTOPATHOLOGICAL FINDINGS :

NON-NEOPLASTIC LESIONS : FEMALE

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Integumentary system/appandage}						
skin/app			<50>	<50>	<50>	<49>
	scab	1+ (%)	0 (0)	0 (0)	1 (2)	0 (0)
		2+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		3+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		4+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
subcutis			<50>	<50>	<50>	<50>
	inflammation	1+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		2+ (%)	0 (0)	1 (2)	0 (0)	0 (0)
		3+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		4+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	exudate	1+ (%)	1 (2)	0 (0)	1 (2)	38 (76)
		2+ (%)	0 (0)	0 (0)	0 (0)	7 (14)
		3+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		4+ (%)	0 (0)	0 (0)	0 (0)	0 (0) **
	eosinophilic change:olfactory epithelium	1+ (%)	22 (44)	21 (42)	19 (38)	12 (24)
		2+ (%)	1 (2)	0 (0)	0 (0)	0 (0)
		3+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		4+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
	eosinophilic change:respiratory epithelium	1+ (%)	29 (58)	24 (48)	22 (44)	22 (44)
		2+ (%)	17 (34)	17 (34)	20 (40)	24 (48)
		3+ (%)	0 (0)	1 (2)	2 (4)	2 (4)
		4+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammation:respiratory epithelium	1+ (%)	2 (4)	1 (2)	10 (20)	32 (64)
		2+ (%)	0 (0)	1 (2)	0 (0)	5 (10)
		3+ (%)	0 (0)	0 (0)	0 (0)	0 (0)
		4+ (%)	0 (0)	0 (0)	0 (0)	0 (0) **

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	respiratory metaplasia:olfactory epithelium		8 (16)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 (0)	6 (12)	1 (2)	0 (0)	0 (0)	36 (72)	8 (16)	0 (0)	0 ** (0)
	respiratory metaplasia:gland		17 (34)	0 (0)	0 (0)	0 (0)	13 (26)	0 (0)	0 (0)	0 (0)	15 (30)	4 (8)	0 (0)	0 (0)	27 (54)	13 (26)	0 (0)	0 ** (0)
	squamous cell metaplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	45 (90)	2 (4)	0 (0)	0 ** (0)
	atrophy:turbinate		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	hyperplasia:transitional epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	septal perforation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	regeneration:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)	43 (86)	7 (14)	0 (0)	0 ** (0)
	atrophy:olfactory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	11 (22)	0 (0)	0 (0)	0 ** (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Respiratory system}																		
nasal cavit			<50>				<50>				<50>				<50>			
	necrosis:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	hyperplasia:respiratory epithelium		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	4 (8)	3 (6)	0 (0)	0 * (0)	20 (40)	8 (16)	0 (0)	0 ** (0)
	adhesion:turbinate		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)
nasopharynx			<50>				<50>				<50>				<50>			
	eosinophilic change		6 (12)	0 (0)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)	5 (10)	1 (2)	0 (0)	0 (0)	10 (20)	1 (2)	0 (0)	0 (0)
lung			<50>				<50>				<50>				<50>			
	hemorrhage		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	edema		10 (20)	0 (0)	0 (0)	0 (0)	9 (18)	2 (4)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)
	deposit of amyloid		1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50				0.1ppm 50				0.4ppm 50				1.6ppm 50			
			1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)	1+ (%)	2+ (%)	3+ (%)	4+ (%)
{Respiratory system}																		
lung			<50>				<50>				<50>				<50>			
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	bronchiolar-alveolar cell hyperplasia		5 (10)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	8 (16)	0 (0)	0 (0)	0 (0)	8 (16)	1 (2)	0 (0)	0 (0)
{Hematopoietic system}																		
bone marrow			<50>				<50>				<50>				<50>			
	increased hematopoiesis		1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	granulopoiesis:increased		5 (10)	0 (0)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	4 (8)	0 (0)	0 (0)	0 (0)
lymph node			<50>				<50>				<50>				<50>			
	deposit of amyloid		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	lymphadenitis		4 (8)	0 (0)	0 (0)	0 (0)	4 (8)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Hematopoietic system}						
thymus			<50>	<50>	<50>	<50>
	atrophy	1+	0 (0)	0 (0)	0 (0)	0 (0)
		2+	0 (0)	1 (2)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
spleen			<50>	<50>	<50>	<50>
	deposit of amyloid	1+	0 (0)	3 (6)	0 (0)	0 (0)
		2+	2 (4)	1 (2)	1 (2)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of hemosiderin	1+	22 (44)	19 (38)	20 (40)	18 (36)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of melanin	1+	0 (0)	1 (2)	0 (0)	0 (0)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	extramedullary hematopoiesis	1+	16 (32)	19 (38)	21 (42)	19 (38)
		2+	2 (4)	4 (8)	4 (8)	2 (4)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	follicular hyperplasia	1+	1 (2)	2 (4)	0 (0)	0 (0)
		2+	1 (2)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
{Circulatory system}						
heart			<50>	<50>	<50>	<50>
	thrombus	1+	0 (0)	0 (0)	1 (2)	1 (2)
		2+	0 (0)	3 (6)	0 (0)	1 (2)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Circulatory system}																		
heart		<50>					<50>				<50>				<50>			
	deposit of amyloid		13 (26)	17 (34)	0 (0)	0 (0)	11 (22)	20 (40)	0 (0)	0 (0)	13 (26)	15 (30)	0 (0)	0 (0)	10 (20)	22 (44)	0 (0)	0 (0)
	mineralization		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	arteritis		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
{Digestive system}																		
tongue		<50>					<50>				<50>				<50>			
	arteritis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
salivary gl		<50>					<50>				<50>				<50>			
	deposit of amyloid		11 (22)	0 (0)	0 (0)	0 (0)	9 (18)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)
	lymphocytic infiltration		1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Digestive system}																		
stomach		<50>																
	deposit of amyloid		46 (92)	0 (0)	0 (0)	0 (0)	44 (88)	0 (0)	0 (0)	0 (0)	45 (90)	2 (4)	0 (0)	0 (0)	43 (86)	0 (0)	0 (0)	0 (0)
	mineralization		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia:forestomach		0 (0)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyperkeratosis:forestomach		26 (52)	13 (26)	0 (0)	0 (0)	27 (54)	17 (34)	0 (0)	0 (0)	20 (40)	17 (34)	0 (0)	0 (0)	24 (48)	14 (28)	0 (0)	0 (0)
	hyperplasia:glandular stomach		22 (44)	27 (54)	0 (0)	0 (0)	13 (26)	37 (74)	0 (0)	0 (0)	5 (10)	44 (88)	0 (0)	0 (0) **	16 (32)	31 (62)	0 (0)	0 (0)
small intes		<50>																
	deposit of amyloid		2 (4)	44 (88)	2 (4)	0 (0)	0 (0)	47 (94)	0 (0)	0 (0)	0 (0)	48 (96)	1 (2)	0 (0)	2 (4)	44 (88)	1 (2)	0 (0)
large intes		<50>																
	deposit of amyloid		19 (38)	1 (2)	0 (0)	0 (0)	16 (32)	2 (4)	0 (0)	0 (0)	14 (28)	1 (2)	0 (0)	0 (0)	22 (44)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Digestive system}																		
liver		<50>					<50>				<50>				<50>			
	angiectasis		1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	necrosis:focal		1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		15 (30)	6 (12)	0 (0)	0 (0)	12 (24)	9 (18)	0 (0)	0 (0)	13 (26)	8 (16)	0 (0)	0 (0)	11 (22)	7 (14)	0 (0)	0 (0)
	inflammatory infiltration		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	inflammatory cell nest		2 (4)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)	3 (6)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	proliferation:histiocyte		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	acidophilic cell focus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
	basophilic cell focus		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Urinary system}																		
kidney		<50>																
	cyst		1 (2)	2 (4)	0 (0)	0 (0)	2 (4)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	hyaline droplet		3 (6)	1 (2)	0 (0)	0 (0)	4 (8)	7 (14)	0 (0)	0 (0)	6 (12)	3 (6)	0 (0)	0 (0)	6 (12)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		7 (14)	24 (48)	2 (4)	0 (0)	3 (6)	25 (50)	4 (8)	0 (0)	2 (4)	21 (42)	5 (10)	0 (0)	11 (22)	21 (42)	1 (2)	0 (0)
	lymphocytic infiltration		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	papillomatous polyp		3 (6)	2 (4)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	2 (4)	0 (0)	0 (0)	0 (0)
	hydronephrosis		2 (4)	6 (12)	1 (2)	0 (0)	3 (6)	6 (12)	0 (0)	0 (0)	2 (4)	6 (12)	1 (2)	1 (2)	2 (4)	5 (10)	2 (4)	0 (0)
	papillary necrosis		4 (8)	1 (2)	0 (0)	0 (0)	8 (16)	2 (4)	0 (0)	0 (0)	7 (14)	5 (10)	0 (0)	0 (0)	8 (16)	2 (4)	0 (0)	0 (0)
	regeneration:proximal tubule		0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	nephrosclerosis	1+	2 (4)	3 (6)	4 (8)	4 (8)
		2+	34 (68)	30 (60)	33 (66)	23 (46)
		3+	1 (2)	0 (0)	1 (2)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
urin bladd			<50>	<50>	<50>	<50>
	dilatation	1+	0 (0)	0 (0)	0 (0)	0 (0)
		2+	3 (6)	0 (0)	0 (0)	2 (4)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	congestion	1+	0 (0)	0 (0)	0 (0)	0 (0)
		2+	0 (0)	0 (0)	0 (0)	1 (2)
		3+	2 (4)	1 (2)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	cyst	1+	0 (0)	0 (0)	0 (0)	0 (0)
		2+	0 (0)	0 (0)	1 (2)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia	1+	2 (4)	4 (8)	0 (0)	1 (2)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)
	Rathke pouch	1+	2 (4)	2 (4)	1 (2)	1 (2)
		2+	0 (0)	0 (0)	0 (0)	0 (0)
		3+	0 (0)	0 (0)	0 (0)	0 (0)
		4+	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Endocrine system}																		
thyroid		<50>																
	vacuolic change		1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	deposit of amyloid		6	0	0	0	3	0	0	0	3	0	0	0	4	0	0	0
			(12)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(6)	(0)	(0)	(0)	(8)	(0)	(0)	(0)
adrenal		<50>																
	deposit of amyloid		5	16	28	0	1	9	40	0	1	9	40	0	2	18	30	0
			(10)	(32)	(56)	(0)	(2)	(18)	(80)	(0)	(2)	(18)	(80)	(0)	(4)	(36)	(60)	(0)
	spindle-cell hyperplasia		3	46	1	0	1	48	1	0	0	48	2	0	2	46	2	0
			(6)	(92)	(2)	(0)	(2)	(96)	(2)	(0)	(0)	(96)	(4)	(0)	(4)	(92)	(4)	(0)
	focal hypertrophy:cortex		0	0	0	0	2	0	0	0	0	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(4)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)
{Reproductive system}																		
ovary		<50>																
	atrophy		0	28	22	0	2	17	31	0 *	0	19	30	0	2	26	22	0
			(0)	(56)	(44)	(0)	(4)	(34)	(62)	(0)	(0)	(38)	(60)	(0)	(4)	(52)	(44)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference : * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	Control 50 1+ (%)	Control 50 2+ (%)	Control 50 3+ (%)	Control 50 4+ (%)	0.1ppm 50 1+ (%)	0.1ppm 50 2+ (%)	0.1ppm 50 3+ (%)	0.1ppm 50 4+ (%)	0.4ppm 50 1+ (%)	0.4ppm 50 2+ (%)	0.4ppm 50 3+ (%)	0.4ppm 50 4+ (%)	1.6ppm 50 1+ (%)	1.6ppm 50 2+ (%)	1.6ppm 50 3+ (%)	1.6ppm 50 4+ (%)
{Reproductive system}																		
ovary		<50>																
	hemorrhage		0	2	0	0	0	6	0	0	0	5	0	0	0	2	1	0
			(0)	(4)	(0)	(0)	(0)	(12)	(0)	(0)	(0)	(10)	(0)	(0)	(0)	(4)	(2)	(0)
	cyst		2	10	0	0	0	10	0	0	0	9	0	0	0	7	0	0
			(4)	(20)	(0)	(0)	(0)	(20)	(0)	(0)	(0)	(18)	(0)	(0)	(0)	(14)	(0)	(0)
	deposit of amyloid		3	15	30	0	3	18	27	0	4	22	22	0	4	28	13	0 **
			(6)	(30)	(60)	(0)	(6)	(36)	(54)	(0)	(8)	(44)	(44)	(0)	(8)	(56)	(26)	(0)
uterus		<50>																
	dilatation		0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)
	cyst		0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0
			(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	hyperplasia:gland		1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			(2)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)
	cystic endometrial hyperplasia		7	1	0	0	10	1	0	0	7	2	0	0	9	4	0	0
			(14)	(2)	(0)	(0)	(20)	(2)	(0)	(0)	(14)	(4)	(0)	(0)	(18)	(8)	(0)	(0)
	xanthogranuloma		0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0
			(0)	(0)	(0)	(0)	(0)	(0)	(0)	(0)	(2)	(0)	(0)	(0)	(0)	(2)	(0)	(0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / Grade	Control 1+ (%)	Control 2+ (%)	Control 3+ (%)	Control 4+ (%)	0.1ppm 1+ (%)	0.1ppm 2+ (%)	0.1ppm 3+ (%)	0.1ppm 4+ (%)	0.4ppm 1+ (%)	0.4ppm 2+ (%)	0.4ppm 3+ (%)	0.4ppm 4+ (%)	1.6ppm 1+ (%)	1.6ppm 2+ (%)	1.6ppm 3+ (%)	1.6ppm 4+ (%)
		No. of Animals on Study	50				50				50				50			
{Reproductive system}																		
vagina		<50>					<50>				<50>				<50>			
	basal cell hyperplasia		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)
{Nervous system}																		
brain		<50>					<50>				<50>				<50>			
	infarct		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)
	deposit of amyloid		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
	mineralization		7 (14)	0 (0)	0 (0)	0 (0)	10 (20)	0 (0)	0 (0)	0 (0)	7 (14)	0 (0)	0 (0)	0 (0)	5 (10)	0 (0)	0 (0)	0 (0)
	gliosis		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)
periph nerv		<50>					<50>				<50>				<50>			
	inflammation		0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	1 (2)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

Organ	Findings	Group Name / No. of Animals on Study / Grade	1+ (%)	2+ (%)	3+ (%)	4+ (%)
		Control 50				
		0.1ppm 50				
		0.4ppm 50				
		1.6ppm 50				
{Special sense organs/appendage}						
Harder gl		Control <50>				
	deposit of amyloid	Control	1 (2)	0 (0)	2 (4)	0 (0)
		0.1ppm	0 (0)	0 (0)	0 (0)	0 (0)
		0.4ppm	0 (0)	1 (2)	0 (0)	0 (0)
		1.6ppm	0 (0)	0 (0)	0 (0)	0 (0)
	hyperplasia	Control	0 (0)	0 (0)	0 (0)	0 (0)
		0.1ppm	0 (0)	0 (0)	0 (0)	0 (0)
		0.4ppm	0 (0)	0 (0)	0 (0)	0 (0)
		1.6ppm	1 (2)	0 (0)	0 (0)	0 (0)
{Musculoskeletal system}						
muscle		Control <50>				
	mineralization	Control	0 (0)	0 (0)	0 (0)	0 (0)
		0.1ppm	0 (0)	0 (0)	0 (0)	0 (0)
		0.4ppm	0 (0)	0 (0)	0 (0)	0 (0)
		1.6ppm	1 (2)	0 (0)	0 (0)	0 (0)

Grade 1+ : Slight 2+ : Moderate 3+ : Marked 4+ : Severe
< a > a : Number of animals examined at the site
b b : Number of animals with lesion
(c) c : b / a * 100
Significant difference ; * : P ≦ 0.05 ** : P ≦ 0.01 Test of Chi Square

TABLE P1

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A1
SEX : MALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
ALL ANIMALS (0- 94W)

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Respiratory system}						
nasal cavit			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	1	0
	metastasis:lymph node tumor		0	0	1	0
lung			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	0	1	1
	metastasis:peritoneum tumor		1	0	0	0
	metastasis:subcutis tumor		0	0	1	0
	metastasis:spleen tumor		1	0	0	0
{Hematopoietic system}						
bone marrow			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	1	0	0
	metastasis:subcutis tumor		0	0	1	0
lymph node			<50>	<50>	<50>	<50>
	metastasis:liver tumor		0	1	0	0
	metastasis:peritoneum tumor		0	1	0	0
	metastasis:spleen tumor		1	0	0	0
spleen			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	2	1	0
	metastasis:liver tumor		0	1	0	0
	metastasis:subcutis tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Hematopoietic system}						
spleen			<50>	<50>	<50>	<50>
	metastasis:lymph node tumor		0	1	0	0
{Digestive system}						
stomach			<50>	<50>	<50>	<50>
	metastasis:peritoneum tumor		1	0	0	0
small intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	1	1
	metastasis:peritoneum tumor		1	1	0	0
large intes			<50>	<50>	<50>	<50>
	metastasis:peritoneum tumor		1	0	0	0
liver			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:peritoneum tumor		1	0	0	0
	metastasis:lymph node tumor		0	0	1	0
pancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
	metastasis:peritoneum tumor		1	0	0	0
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:liver tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	metastasis:lymph node tumor		0	0	1	0
{Endocrine system}						
adrenal			<50>	<50>	<50>	<50>
	metastasis:peritoneum tumor		1	0	0	0
{Reproductive system}						
epididymis			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:peritoneum tumor		0	1	0	0
semin ves			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	0
	metastasis:peritoneum tumor		0	1	0	0
prostate			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	1	0	0
	metastasis:peritoneum tumor		0	1	0	0
{Body cavities}						
mediastinum			<50>	<50>	<50>	<50>
	metastasis:peritoneum tumor		0	1	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE P2

HISTOPATHOLOGICAL FINDINGS :

METASTASIS OF TUMOR :

FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
REPORT TYPE : A2
SEX : FEMALE

HISTOPATHOLOGICAL FINDINGS : METASTASIS OF TUMOR (SUMMARY)
ALL ANIMALS (0-100W)

Organ	Findings	Control	0.1ppm	0.4ppm	1.6ppm
Group Name		Control	0.1ppm	0.4ppm	1.6ppm
No. of Animals on Study		50	50	50	50
{Integumentary system/appandage}					
skin/app		<50>	<50>	<50>	<49>
	leukemic cell infiltration	0	0	1	1
subcutis		<50>	<50>	<50>	<50>
	leukemic cell infiltration	0	0	1	0
	metastasis:bone tumor	1	0	0	0
{Respiratory system}					
nasal cavit		<50>	<50>	<50>	<50>
	leukemic cell infiltration	1	0	0	1
lung		<50>	<50>	<50>	<50>
	leukemic cell infiltration	5	5	1	6
	metastasis:liver tumor	0	1	0	1
	metastasis:uterus tumor	1	0	3	0
	metastasis:subcutis tumor	1	0	0	0
	metastasis:spleen tumor	0	0	1	0
{Hematopoietic system}					
bone marrow		<50>	<50>	<50>	<50>
	leukemic cell infiltration	2	2	2	4
	metastasis:liver tumor	0	2	0	2
	metastasis:uterus tumor	1	2	3	3
lymph node		<50>	<50>	<50>	<50>
	metastasis:liver tumor	0	1	0	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Hematopoietic system}						
lymph node			<50>	<50>	<50>	<50>
	metastasis:uterus tumor		0	1	1	1
	metastasis:subcutis tumor		1	0	1	0
	metastasis:spleen tumor		0	0	2	0
spleen			<50>	<50>	<50>	<50>
	leukemic cell infiltration		9	4	3	9
	metastasis:liver tumor		0	2	0	1
	metastasis:uterus tumor		1	1	0	1
{Circulatory system}						
heart			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	1
{Digestive system}						
tongue			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	0	1
salivary gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	1	1	2
	metastasis:liver tumor		0	0	0	1
stomach			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	0	0	0
	metastasis:uterus tumor		0	0	0	1

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control	0.1ppm	0.4ppm	1.6ppm
			50	50	50	50
{Digestive system}						
small intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		2	0	1	0
	metastasis:subcutis tumor		0	0	0	1
anus			<50>	<50>	<50>	<50>
	metastasis:subcutis tumor		0	0	1	0
large intes			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
liver			<50>	<50>	<50>	<50>
	leukemic cell infiltration		6	4	3	5
	metastasis:uterus tumor		4	8	8	5
	metastasis:subcutis tumor		1	0	0	0
	metastasis:spleen tumor		0	0	0	1
gall bladd			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	0
pancreas			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	1	4
	metastasis:uterus tumor		1	1	1	1
	metastasis:subcutis tumor		1	0	0	0
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	leukemic cell infiltration		5	5	3	8

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Urinary system}						
kidney			<50>	<50>	<50>	<50>
	metastasis:uterus tumor		0	0	0	2
urin bladd			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	1	0
{Endocrine system}						
pituitary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
adrenal			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
	metastasis:uterus tumor		1	1	0	1
	metastasis:subcutis tumor		1	0	0	0
{Reproductive system}						
ovary			<50>	<50>	<50>	<50>
	leukemic cell infiltration		3	1	1	2
	metastasis:uterus tumor		4	5	5	5
	metastasis:spleen tumor		0	0	0	1
uterus			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	0	1
	metastasis:subcutis tumor		1	0	0	0
vagina			<50>	<50>	<50>	<50>
	metastasis:uterus tumor		0	0	1	0

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

Organ	Findings	Group Name / No. of Animals on Study	Control 50	0.1ppm 50	0.4ppm 50	1.6ppm 50
{Nervous system}						
brain			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	0	0	1
{Special sense organs/appendage}						
Harder gl			<50>	<50>	<50>	<50>
	leukemic cell infiltration		1	1	3	3
{Musculoskeletal system}						
muscle			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
	metastasis:subcutis tumor		1	0	0	0
{Body cavities}						
mediastinum			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	0
peritoneum			<50>	<50>	<50>	<50>
	leukemic cell infiltration		0	0	1	3
	metastasis:uterus tumor		0	3	3	2

< a > a : Number of animals examined at the site
b b : Number of animals with lesion

TABLE Q1

CAUSE OF DEATH : MALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : MALE

COUSE OF DEATH (SUMMARY)
(0- 94W), (0-100W)

Group Name	Control	0.1ppm	0.4ppm	1.6ppm
Number of Dead and Moribund Animal	39	35	36	35
renal lesion	22	17	19	21
urinary retention	2	6	4	1
amyloidosis	10	6	6	7
arteritis	0	0	0	1
hydronephrosis	3	2	4	2
tumor d:leukemia	0	1	1	2
tumor d:subcutis	0	0	1	0
tumor d:spleen	1	0	0	0
tumor d:liver	0	2	1	1
tumor d:peritoneum	1	1	0	0

TABLE Q2

CAUSE OF DEATH : FEMALE

STUDY NO. : 0817
ANIMAL : MOUSE B6D2F1/Crlj[Crj:BDF1]
SEX : FEMALE

COUSE OF DEATH (SUMMARY)
(0- 94W), (0-100W)

Group Name	Control	0.1ppm	0.4ppm	1.6ppm
Number of Dead and Moribund Animal	39	32	36	31
no microscop confirm	0	2	0	1
renal lesion	16	8	14	8
periph nerves lesion	0	0	1	0
thrombosis	0	1	0	1
amyloidosis	7	10	10	4
hydronephrosis	1	0	1	2
tumor d:leukemia	5	3	1	6
tumor d:subcutis	3	0	2	0
tumor d:spleen	0	0	1	1
tumor d:liver	1	2	0	3
tumor d:uterus	5	6	6	5
tumor d:bone	1	0	0	0